RESULT_COUNT: 621,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-10-19 12:06:00 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120600469.html?.tsrc=rss,"Index (PMI) data, output in the Healthcare sector is rising.  To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way."
SGEN,SGEN:UW,BBG000BH0SG0,Cramer’s Exec Cut: CEO reveals his company’s plans to dis...,2017-10-13 23:13:00 +0000,https://finance.yahoo.com/video/cramer-exec-cut-ceo-reveals-231300790.html?.tsrc=rss,"Jim Cramer spoke with an array of executives to talk 3-D printing, earnings, the future of oil and much more."
SGEN,SGEN:UW,BBG000BH0SG0,Cancer Space Update: Lung & Breast Cancer Studies in Focus,2017-10-13 17:12:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICWbxtpsd28/cancer-space-update-lung-breast-cancer-studies-in-focus-cm859512,Major news in the cancer segment this week was the failure of Eli Lilly and Company s LLY newly approved breast cancer drug Verzenio in a pivotal lung cancer study With this latest failure Lilly joins the list of large pharma companies who have failed in their respective lung cancer
SGEN,SGEN:UW,BBG000BH0SG0,Cancer Space Update: Lung & Breast Cancer Studies in Focus,2017-10-13 15:18:03 +0000,https://finance.yahoo.com/news/cancer-space-lung-breast-cancer-151803744.html?.tsrc=rss,"While Lilly announced failure of a lung cancer study, AstraZeneca&apos;s Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Inks Clinical Collaborations for Cancer Drug,2017-10-12 14:18:02 +0000,https://finance.yahoo.com/news/seattle-genetics-inks-clinical-collaborations-141802190.html?.tsrc=rss,Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.
SGEN,SGEN:UW,BBG000BH0SG0,Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics,2017-10-12 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-122000049.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / October 12, 2017 / Both Akari Therapeutics and Seattle Genetics saw their shares climb higher on Wednesday after the companies had encouraging news about clinical trials. While ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Cramer Remix: It’s not about sex appeal, it’s about timin...",2017-10-11 23:10:00 +0000,https://finance.yahoo.com/video/cramer-remix-not-sex-appeal-231000256.html?.tsrc=rss,"Jim Cramer didn’t offer up dating advice, he focused on one stock you should have on your radar."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics CEO talks new cancer treatment pipeline,...",2017-10-11 23:02:00 +0000,https://finance.yahoo.com/video/seattle-genetics-ceo-talks-cancer-230200520.html?.tsrc=rss,"Jim Cramer sat down with Clay Siegall, the co-founder, chairman and CEO of Seattle Genetics, to hear more about his company's pipeline."
SGEN,SGEN:UW,BBG000BH0SG0,"Cramer Remix: It’s not about sex appeal, it’s about timing",2017-10-11 22:59:51 +0000,http://finance.yahoo.com/r/86dbb7b4-5cd5-3a09-8bad-281efb2e1d18/104766347?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104766347&yptr=yahoo&.tsrc=rss,"Jim Cramer didn’t offer up dating advice, he focused on one stock you should have on your radar."
SGEN,SGEN:UW,BBG000BH0SG0,This Drugmaker Hit A 4-Month High On Collaboration With Dow's Merck,2017-10-11 22:12:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d_bPaEfajic/this-drugmaker-hit-a-4-month-high-on-collaboration-with-dows-merck-cm858483,Seattle Genetics SGEN launched to its highest point in four months Wednesday after announcing a series of cancer drug trials with Dow component Merck MRK and Japanese drugmaker Astellas Pharma ibd display video id 2350024 width 50 float left autostart true By
SGEN,SGEN:UW,BBG000BH0SG0,"AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back",2017-10-11 21:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/udFdET8qXwM/aeri-faces-dday-pti-to-report-data-in-q4-mack-makes-peace-mnkd-pulls-back-20171011-01296,"AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back"
SGEN,SGEN:UW,BBG000BH0SG0,"Why Snap, Seattle Genetics, and Pretium Resources Jumped Today",2017-10-11 21:03:21 +0000,https://finance.yahoo.com/news/why-snap-seattle-genetics-pretium-210321208.html?.tsrc=rss,These stocks led the market higher. Find out why.
SGEN,SGEN:UW,BBG000BH0SG0,This Drugmaker Hit A 4-Month High On Collaboration With Dow&apos;s Merck,2017-10-11 20:38:52 +0000,http://finance.yahoo.com/r/fdf65c62-3eb6-3531-98a8-c8deaeae76fc/this-drugmaker-hit-a-4-month-high-on-collaboration-with-dows-merck?src=A00220&yptr=yahoo&.tsrc=rss,Seattle Genetics launched to its highest point in four months on a series of cancer drug trials with Merck and Astellas Pharma.
SGEN,SGEN:UW,BBG000BH0SG0,SGEN Makes Bullish Cross Above Critical Moving Average,2017-10-11 17:13:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6Yj9xehqR5U/sgen-makes-bullish-cross-above-critical-moving-average-cm858286,In trading on Wednesday shares of Seattle Genetics Inc Symbol SGEN crossed above their 200 day moving average of 58 89 changing hands as high as 61 85 per share Seattle Genetics Inc shares are currently trading up about 6 8 on the day The chart below shows the one year performance of
SGEN,SGEN:UW,BBG000BH0SG0,SGEN Makes Bullish Cross Above Critical Moving Average,2017-10-11 17:13:16 +0000,,In trading on Wednesday shares of Seattle Genetics Inc Symbol SGEN crossed above their 200 day moving average of 58 89 changing hands as high as 61 85 per share Seattle Genetics Inc shares are currently trading up about 6 8 on the day The chart below shows the one year performance of
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Begins Phase II Study of Cancer Candidate,2017-10-11 14:29:02 +0000,https://finance.yahoo.com/news/seattle-genetics-begins-phase-ii-142902075.html?.tsrc=rss,Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer,2017-10-11 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-announces-additional-clinical-120000671.html?.tsrc=rss,"Seattle Genetics, Inc. today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer . SGN-LIV1A is an investigational antibody-drug conjugate that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, ovarian, and cervical cancers."
SGEN,SGEN:UW,BBG000BH0SG0,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4",2017-10-11 01:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EzjObddRtQY/cry-opens-wallet-llys-juniper-flops-mdxg-catches-eyes-rnn-awaits-data-in-q4-20171011-00020,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4"
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-10-10 12:05:45 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120545670.html?.tsrc=rss,Seattle Genetics Inc NASDAQ/NGS:SGEN
SGEN,SGEN:UW,BBG000BH0SG0,Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer,2017-10-10 12:00:00 +0000,https://finance.yahoo.com/news/astellas-seattle-genetics-initiate-pivotal-120000344.html?.tsrc=rss,"TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, ""Astellas"") and Seattle Genetics Inc., (SGEN) today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy.  The EV-201 study will assess the antitumor activity and safety of enfortumab vedotin to support potential registration under the U.S. Food and Drug Administration's (FDA) accelerated approval regulations.  In addition, there are no FDA-approved therapies for patients who progress following CPI treatment,"" said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer,2017-10-10 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-astellas-initiate-pivotal-120000198.html?.tsrc=rss,"Seattle Genetics, Inc. and Astellas Pharma Inc. today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor therapy."
SGEN,SGEN:UW,BBG000BH0SG0,Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer,2017-10-10 10:44:00 +0000,https://finance.yahoo.com/news/genmab-seattle-genetics-initiate-study-104400119.html?.tsrc=rss,"Genmab A/S and Seattle Genetics, Inc. announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer."
SGEN,SGEN:UW,BBG000BH0SG0,Cancer Space Last Week Update: Pipeline Expansion in Focus,2017-10-09 14:13:02 +0000,https://finance.yahoo.com/news/cancer-space-last-week-pipeline-141302097.html?.tsrc=rss,"Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-10-06 12:05:57 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120557929.html?.tsrc=rss,Seattle Genetics Inc NASDAQ/NGS:SGEN
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-10-05 12:05:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120551965.html?.tsrc=rss,Seattle Genetics Inc NASDAQ/NGS:SGEN
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017",2017-10-05 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-host-conference-call-120000189.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that it will report its third quarter financial results on Thursday, October 26, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update."
SGEN,SGEN:UW,BBG000BH0SG0,Cramer's lightning round: Why my charitable trust sold it...,2017-10-04 23:03:00 +0000,https://finance.yahoo.com/video/cramers-lightning-round-why-charitable-230300115.html?.tsrc=rss,"Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one at risk of being &quot;Amazon-ed.&quot;"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reaches Analyst Target Price,2017-10-03 16:58:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pXy4TkU78jc/seattle-genetics-reaches-analyst-target-price-cm854652,In recent trading shares of Seattle Genetics Inc Symbol SGEN have crossed above the average analyst 12 month target price of 57 30 changing hands for 58 72 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher,2017-10-03 15:01:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/26si-ojWic4/seattle-genetics-sgen-in-focus-stock-moves-79-higher-cm854440,Seattle Genetics Inc SGEN was a big mover last session as the company saw its shares rise nearly 8 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company for the company as the stock is
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' Adcetris Gets Breakthrough Therapy Status,2017-10-03 14:57:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8N3b6n3Bcec/seattle-genetics-adcetris-gets-breakthrough-therapy-status-cm854532,Seattle Genetics Inc SGEN announced that the FDA has granted Breakthrough Therapy Designation status to its lymphoma drug Adcetris as frontline treatment for advanced classical Hodgkin lymphoma The company recently completed a phase III study ECHELON 1 on the drug for this
SGEN,SGEN:UW,BBG000BH0SG0,"Company News For Oct 3, 2017",2017-10-03 14:54:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NFM8ks61KsE/company-news-for-oct-3-2017-cm854488,Shares of Cal Maine Foods Inc CALM surged 1 3 after posting first quarter 2018 revenue of 263 million higher than 240 million from year ago quarter General Electric s GE shares gained 1 6 after the company entered into an agreement with a French company Suez to sell its
SGEN,SGEN:UW,BBG000BH0SG0,Green Monday for Capital Markets Around the Globe,2017-10-03 14:46:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VK6qsrvouqQ/green-monday-for-capital-markets-around-the-globe-cm854499,The U S stock market indexes opened in green Monday The S amp P 500 the Nasdaq and the Dow Jones started the week with gains The U S stock market indexes opened in green Monday The S P 500 the Nasdaq and the Dow Jones started the week with gains Shares of Seattle Genetics Inc
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics&apos; Adcetris Gets Breakthrough Therapy Status,2017-10-03 13:40:01 +0000,https://finance.yahoo.com/news/seattle-genetics-apos-adcetris-gets-134001492.html?.tsrc=rss,"Seattle Genetics&apos; (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher,2017-10-03 12:57:12 +0000,https://finance.yahoo.com/news/seattle-genetics-sgen-focus-stock-125712466.html?.tsrc=rss,"Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,2017-10-03 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-takeda-announce-publication-120000995.html?.tsrc=rss,"Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced final data from the ADCETRIS pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma were published in the journal Blood."
SGEN,SGEN:UW,BBG000BH0SG0,Biotech's Breakout To Start In The Fourth Quarter,2017-10-03 10:00:00 +0000,http://finance.yahoo.com/r/68f7d93b-1254-3ec9-8ca0-5958fa6a8ba9/biotechs-breakout-start-fourth-quarter?partner=YahooSA&yptr=yahoo&.tsrc=rss,The biotechnology sector appears to soar as we enter the final quarter of 2017.
SGEN,SGEN:UW,BBG000BH0SG0,Green Monday for Capital Markets Around the Globe,2017-10-02 19:03:48 +0000,https://finance.yahoo.com/news/green-monday-capital-markets-around-190348152.html?.tsrc=rss,Seattle Genetics rises in premarket trading
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma,2017-10-02 10:45:00 +0000,https://finance.yahoo.com/news/seattle-genetics-receives-fda-breakthrough-104500166.html?.tsrc=rss,"Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' ADCETRIS Gets FDA Breakthrough Therapy Designation,2017-10-02 07:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dd_z-fQLIcQ/seattle-genetics-adcetris-gets-fda-breakthrough-therapy-designation-20171002-00344,Seattle Genetics' ADCETRIS Gets FDA Breakthrough Therapy Designation
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-09-27 12:06:48 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120648354.html?.tsrc=rss,Seattle Genetics Inc NASDAQ/NGS:SGEN
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer,2017-09-25 14:52:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P5enUOzxSXY/bristol-myers-bmy-opdivo-gets-approval-for-liver-cancer-cm850329,Bristol Myers Squibb Company BMY announced that the FDA has approved immuno oncology drug Opdivo for intravenous use for patients with hepatocellular carcinoma HCC who have been previously treated with 160 Nexavar The approval for this indication was granted under accelerated approval
SGEN,SGEN:UW,BBG000BH0SG0,"ETFs with exposure to Seattle Genetics, Inc. : September 25, 2017",2017-09-25 14:45:42 +0000,http://finance.yahoo.com/r/1289e7a0-247c-3e50-8713-ff7a69680a17/etfs-with-exposure-to-seattle-genetics-inc-september-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer,2017-09-25 12:35:12 +0000,https://finance.yahoo.com/news/bristol-myers-bmy-opdivo-gets-123512253.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.
SGEN,SGEN:UW,BBG000BH0SG0,Is Seattle Genetics Inc (SGEN) Undervalued?,2017-09-17 21:43:14 +0000,https://finance.yahoo.com/news/seattle-genetics-inc-sgen-undervalued-214314887.html?.tsrc=rss,"Seattle Genetics Inc (NASDAQ:SGEN), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a decent share price growth in the teens level on the NasdaqGS over theRead More..."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-09-14 12:06:33 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120633886.html?.tsrc=rss,Seattle Genetics Inc NASDAQ/NGS:SGEN
SGEN,SGEN:UW,BBG000BH0SG0,"ETFs with exposure to Seattle Genetics, Inc. : September 14, 2017",2017-09-14 00:28:45 +0000,http://finance.yahoo.com/r/76bf2405-dc13-3e89-8464-d653b672f141/etfs-with-exposure-to-seattle-genetics-inc-september-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics To Present At Morgan Stanley Conference; Webcast At 2:05 PM ET,2017-09-12 13:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hKOODZ5mgqg/seattle-genetics-to-present-at-morgan-stanley-conference-webcast-at-205-pm-et-20170912-01135,Seattle Genetics To Present At Morgan Stanley Conference; Webcast At 2:05 PM ET
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017",2017-09-11 18:09:32 +0000,http://finance.yahoo.com/r/6a816a79-e8df-3ec4-b665-ee2a21cb8f25/seattle-genetics-inc-sgen-us-earnings-analysis-q2-2017-by-the-numbers-september-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Seattle Genetics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Seattle Genetics, Inc. – ImmunoGen, Inc., Biogen Inc., Celgene Corporation, Celldex Therapeutics, Inc., Pfizer Inc., GlaxoSmithKline plc Sponsored ADR, Spectrum Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Progenics Pharmaceuticals, Inc. ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Bristol-Myers' Opdivo Study Meets Early Success, Stock Up",2017-09-08 15:55:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SVbtogYJDoM/bristol-myers-opdivo-study-meets-early-success-stock-up-cm842946,Shares of Bristol Myers Squibb Company BMY gained about 5 after the company ended its phase III combination study CheckMate 214 earlier than expected after it met its co primary endpoint The phase III study evaluated Opdivo plus Yervoy in patients with previously untreated advanced
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-09-08 14:25:45 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-142545228.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress,2017-09-08 14:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-highlights-promising-data-140000425.html?.tsrc=rss,"Seattle Genetics, Inc. today announced that preliminary clinical data for tisotumab vedotin from a Genmab-sponsored phase 1/2 clinical trial are being featured in an oral presentation at the European Society for Medical Oncology Congress being held September 8-12, 2017 in Madrid, Spain."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference,2017-09-06 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-present-morgan-stanley-120000726.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 2:05 p.m. EDT."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-09-05 12:05:09 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120509644.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA,2017-09-04 15:49:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dUP9K9NnRcE/pfizers-acute-leukemia-drug-mylotarg-approved-by-the-fda-cm840773,Pfizer Inc PFE announced that the FDA has granted approval to Mylotarg for adult patients with newly diagnosed CD33 positive acute myeloid leukemia AML The drug also received approval to treat relapsed or refractory CD33 positive AML in adults as well as children 2 years and older
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : September 1, 2017",2017-09-01 14:09:08 +0000,http://finance.yahoo.com/r/64b464fe-09da-3ae1-b3d1-0ecf393d075f/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-september-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,Today's Research Reports on Stocks to Watch: Seattle Genetics and Novartis,2017-09-01 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000053.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 1, 2017 / Shares of Seattle Genetics closed higher on Thursday as more traders digested the big news from the company earlier in the week when it announced that it ..."
SGEN,SGEN:UW,BBG000BH0SG0,Analysts Predict 12% Gains Ahead For FBT,2017-08-31 13:52:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gbtwCgGAZMI/analysts-predict-12-gains-ahead-for-fbt-cm839559,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-08-31 12:11:18 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-121118699.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-08-30 12:06:04 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120604918.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors,2017-08-29 11:05:00 +0000,https://finance.yahoo.com/news/genmab-seattle-genetics-co-develop-110500435.html?.tsrc=rss,"Genmab A/S and Seattle Genetics, Inc. announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development."
SGEN,SGEN:UW,BBG000BH0SG0,Genmab: Seattle Genetics Exercises Option To Co-develop Tisotumab Vedotin,2017-08-29 06:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/78gNmjlphH8/genmab-seattle-genetics-exercises-option-to-codevelop-tisotumab-vedotin-20170829-00257,Genmab: Seattle Genetics Exercises Option To Co-develop Tisotumab Vedotin
SGEN,SGEN:UW,BBG000BH0SG0,Unum Therapeutics: IND Application Active For ACTR087 With SEA-BCMA,2017-08-23 08:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bgWTs9K2wy4/unum-therapeutics-ind-application-active-for-actr087-with-seabcma-20170823-00428,Unum Therapeutics: IND Application Active For ACTR087 With SEA-BCMA
SGEN,SGEN:UW,BBG000BH0SG0,First Week of SGEN October 20th Options Trading,2017-08-22 16:40:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vIbTYbh_0N8/first-week-of-sgen-october-20th-options-trading-cm835391,Investors in Seattle Genetics Inc Symbol SGEN saw new options become available this week for the October 20th expiration At Stock Options Channel our YieldBoost formula has looked up and down the SGEN options chain for the new October 20th contracts and identified one put and one
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' Adcetris Granted Priority Review by FDA,2017-08-18 00:37:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ie9rpF0p9zE/seattle-genetics-adcetris-granted-priority-review-by-fda-cm833667,Seattle Genetics Inc SGEN announced that the FDA has accepted its supplemental Biologics License Application BLA for Adcetris brentuximab vedotin in patients with cutaneous T cell lymphoma CTCL Additionally the FDA granted Priority Review for the application and has set a target
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics&apos; Adcetris Granted Priority Review by FDA,2017-08-17 22:33:10 +0000,https://finance.yahoo.com/news/seattle-genetics-apos-adcetris-granted-223310071.html?.tsrc=rss,"Seattle Genetics, Inc.&apos;s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review."
SGEN,SGEN:UW,BBG000BH0SG0,"ABIO To Report Data In Q1; IOVA Fired Up, PMD In Iowa, VRX All Cleared",2017-08-17 01:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1207DPzn_rk/abio-to-report-data-in-q1-iova-fired-up-pmd-in-iowa-vrx-all-cleared-20170817-00031,"ABIO To Report Data In Q1; IOVA Fired Up, PMD In Iowa, VRX All Cleared"
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-08-16 12:06:01 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120601904.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma,2017-08-16 12:00:00 +0000,https://finance.yahoo.com/news/fda-accepts-supplemental-biologics-license-120000227.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing a supplemental Biologics License Application based on data from the phase 3 ALCANZA trial and two phase 2 investigator-sponsored trials of ADCETRIS in patients with cutaneous T-cell lymphoma ."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-08-15 12:06:23 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120623926.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-08-12 12:07:20 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120720287.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,Edited Transcript of SGEN earnings conference call or presentation 27-Jul-17 8:30pm GMT,2017-08-11 23:31:02 +0000,https://finance.yahoo.com/news/edited-transcript-sgen-earnings-conference-123521821.html?.tsrc=rss,Q2 2017 Seattle Genetics Inc Earnings Call
SGEN,SGEN:UW,BBG000BH0SG0,"IHS Markit Score upgrades Seattle Genetics Inc to 75 out of 100, despite ranking positively in only one IHS Markit category.",2017-08-10 12:07:13 +0000,https://finance.yahoo.com/news/ihs-markit-score-upgrades-seattle-120713355.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,See what the IHS Markit Score report has to say about Seattle Genetics Inc.,2017-08-09 12:05:35 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120535007.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SGEN,SGEN:UW,BBG000BH0SG0,Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen,2017-08-04 11:40:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-paul-sekhri-114000887.html?.tsrc=rss,"Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ..."
SGEN,SGEN:UW,BBG000BH0SG0,Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis,2017-08-03 11:10:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-vertex-pharma-111000064.html?.tsrc=rss,"Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 3, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb,2017-08-01 20:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-announces-purchase-bothell-200000300.html?.tsrc=rss,"Seattle Genetics, Inc. , a biotechnology company, today announced that it has signed definitive agreements to purchase Bristol-Myers Squibb’s pharmaceutical manufacturing facility in Bothell, Washington."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)",2017-07-31 21:55:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TAX1y0cqXKc/seattle-genetics-inc-expanded-sales-on-their-way-fda-willing-cm824574,Seattle Genetics NASDAQ SGEN reported second quarter revenue and earnings numbers but the conference call focused mostly on potential near term revenue growth for the biotech s one approved drug Adcetris with one expanded indication under review at the FDA and another to be
SGEN,SGEN:UW,BBG000BH0SG0,"ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down",2017-07-31 20:56:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z7xbm34ZgGs/immunogen-inc-earnings-what-goes-up-must-come-down-cm824502,After popping 14 on Friday follow earnings that didn t justify the increase shares of ImmunoGen NASDAQ IMGN are down 12 6 at 2 49 p m EDT on Monday also for no apparent reason The biotech reported 160 second quarter earnings on Friday but without any revenue
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)",2017-07-31 20:00:00 +0000,http://finance.yahoo.com/r/42bc075a-b672-3fc3-9460-b624c5adb12d/seattle-genetics-inc-expanded-sales-on-their-way-f.aspx?yptr=yahoo&.tsrc=rss,"A solid quarter from the biotech, but further substantial sales growth will only come from more FDA approvals."
SGEN,SGEN:UW,BBG000BH0SG0,"ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down",2017-07-31 19:19:44 +0000,http://finance.yahoo.com/r/3020df17-7af9-3932-840b-973f6a06b40c/immunogen-inc-earnings-what-goes-up-must-come-down.aspx?yptr=yahoo&.tsrc=rss,The biotech experiences an earnings pop and drop.
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Q2 Loss Narrower than Expected,2017-07-28 16:59:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dKt87_okxfg/seattle-genetics-sgen-q2-loss-narrower-than-expected-cm823353,Seattle Genetics Inc SGEN reported a loss of 39 cents per share for the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 43 cents but wider than the year ago loss of 23 cents per share Revenues came in at 108 2 million up 13 4 year over year primarily on
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Q2 Loss Narrower than Expected,2017-07-28 15:16:03 +0000,https://finance.yahoo.com/news/seattle-genetics-sgen-q2-loss-151603965.html?.tsrc=rss,Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 2Q loss,2017-07-27 21:58:59 +0000,https://finance.yahoo.com/news/seattle-genetics-reports-2q-loss-215859120.html?.tsrc=rss,"The Bothell, Washington-based company said it had a loss of 39 cents per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Second Quarter 2017 Financial Results,2017-07-27 20:02:00 +0000,https://finance.yahoo.com/news/seattle-genetics-reports-second-quarter-200200105.html?.tsrc=rss,"Seattle Genetics, Inc. today reported financial results for the second quarter ended June 30, 2017. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, enfortumab vedotin clinical activities, as well as progress with its pipeline of antibody-drug conjugates and other proprietary programs."
SGEN,SGEN:UW,BBG000BH0SG0,"Investor Network: Seattle Genetics, Inc. to Host Earnings Call",2017-07-27 14:45:00 +0000,https://finance.yahoo.com/news/investor-network-seattle-genetics-inc-144500386.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 27, 2017 / Seattle Genetics, Inc. (NASDAQ: SGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, July 27, 2017 at 4:30 PM Eastern ..."
SGEN,SGEN:UW,BBG000BH0SG0,Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression,2017-07-25 12:00:00 +0000,https://finance.yahoo.com/news/health-canada-approves-adcetris-brentuximab-120000238.html?.tsrc=rss,"Seattle Genetics, Inc. today announced that Health Canada has issued a non-conditional marketing authorization for use of ADCETRIS as post-autologous stem cell transplant consolidation treatment of patients with Hodgkin lymphoma at increased risk of relapse or progression."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Gets Canadian Marketing Authorization For Adcetris,2017-07-25 08:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l1p7R65FfvM/seattle-genetics-gets-canadian-marketing-authorization-for-adcetris-20170725-00715,Seattle Genetics Gets Canadian Marketing Authorization For Adcetris
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer,2017-07-24 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-announces-clinical-collaboration-120000771.html?.tsrc=rss,"Seattle Genetics, Inc. , a global biotechnology company, today announced a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug conjugate SGN-LIV1A in combination with atezolizumab in patients with metastatic triple-negative breast cancer ."
SGEN,SGEN:UW,BBG000BH0SG0,"The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals",2017-07-14 15:50:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zKyeyvzUoxU/the-zacks-analyst-blog-highlights-merck-celgene-gilead-sciences-seattle-genetics-and-vanda-pharmaceuticals-cm816182,For Immediate Release Chicago IL July 14 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
SGEN,SGEN:UW,BBG000BH0SG0,"The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals",2017-07-14 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-merck-133001779.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals"
SGEN,SGEN:UW,BBG000BH0SG0,5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates,2017-07-13 20:48:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/72ahbCpx_e4/5-drug-stocks-well-poised-to-beat-q2-earnings-estimates-cm815825,The pharma biotech sector has picked up this year after being battered by the drug pricing controversy in 2016 The first half has been pretty strong for companies in the space The NYSE ARCA Pharmaceutical Index has risen almost 9 8 year to date YTD after declining almost 10 last
SGEN,SGEN:UW,BBG000BH0SG0,5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates,2017-07-13 18:31:06 +0000,https://finance.yahoo.com/news/5-drug-stocks-well-poised-183106599.html?.tsrc=rss,The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.
SGEN,SGEN:UW,BBG000BH0SG0,Pfizer's Mylotarg Recommended by FDA Advisory Committee,2017-07-12 16:48:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/foVV7GO0ATc/pfizers-mylotarg-recommended-by-fda-advisory-committee-cm815128,Pfizer Inc PFE announced that the FDA s Oncologic Drug Advisory Committee ODAC voted in favor of Mylotarg for the treatment of patients with newly diagnosed CD33 positive acute myeloid leukemia AML The committee believes that the ALFA 0701 study investigating Mylotarg provides
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study,2017-07-06 20:45:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pdD4wFbda1M/bristol-myers-opdivo-superior-to-yervoy-in-melanoma-study-cm812657,Bristol Myers Squibb Company BMY announced that a phase III study CheckMate 238 evaluating Opdivo 3 mg kg versus Yervoy 10 mg kg met its primary endpoint at a planned interim analysis The study evaluated patients with stage IIIb c or stage IV melanoma who are at high risk of
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017",2017-07-06 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-host-conference-call-120000642.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that it will report its second quarter financial results on Thursday, July 27, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update."
SGEN,SGEN:UW,BBG000BH0SG0,What Analysts Recommend for United Therapeutics in June 2017,2017-07-04 14:37:39 +0000,http://finance.yahoo.com/r/8a7b600d-8566-38d4-b274-1e11694167e7/what-analysts-recommend-for-united-therapeutics-in-june-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”
SGEN,SGEN:UW,BBG000BH0SG0,Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU,2017-06-30 15:44:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tIC6fRN0h_k/roches-rhhby-leukemia-drug-gets-prime-status-in-eu-cm810572,The European Medicines Agency EMA granted PRIME PRIorityMEdicines designation to Roche Holdings AG s RHHBY investigational drug polatuzumab vedotin in combination with MabThera and bendamustine The drug will be used to treat patients with relapsed or refractory diffuse large B cell
SGEN,SGEN:UW,BBG000BH0SG0,FBT's Underlying Holdings Could Mean 11% Gain Potential,2017-06-28 13:49:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iExPAbG1c_8/fbts-underlying-holdings-could-mean-11-gain-potential-cm809205,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Reports Positive Data for Adcetris,2017-06-27 16:52:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1bRNGywOc4U/seattle-genetics-sgen-reports-positive-data-for-adcetris-cm808886,Seattle Genetics Inc SGEN and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study ECHLEON 1 study evaluating Adcetris brentuximab vedotin as part of a frontline combination chemotherapy regimen in patients with previously untreated advanced
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Reports Positive Data for Adcetris,2017-06-27 14:48:02 +0000,https://finance.yahoo.com/news/seattle-genetics-sgen-reports-positive-144802378.html?.tsrc=rss,"Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study."
SGEN,SGEN:UW,BBG000BH0SG0,Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics,2017-06-27 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000524.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 27, 2017 / The Dow and S&P 500 eked out modest gains on Monday, despite a poor performance from the technology sector. The Dow Jones Industrial Average gained 0.07 percent ..."
SGEN,SGEN:UW,BBG000BH0SG0,Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers,2017-06-27 01:32:00 +0000,http://finance.yahoo.com/r/9925331a-89a8-351e-9199-96b62c122441/biotech-movers-seattle-genetics-fibrogen-sangamo.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Seattle Genetics, FibroGen and Sangamo were among the biotech stock movers in premarket trading on June 26."
SGEN,SGEN:UW,BBG000BH0SG0,"Why Frontier Communications, Seattle Genetics, and Arconic Slumped Today",2017-06-26 22:50:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t-WAQau9jnQ/why-frontier-communications-seattle-genetics-and-arconic-slumped-today-cm808376,Monday ended quietly on Wall Street with the Dow and S amp P 500 moving higher by less than a tenth of a percentage point The Nasdaq went in the opposite direction falling more than a quarter percent as investors favored more defensively positioned companies over
SGEN,SGEN:UW,BBG000BH0SG0,"Gainers & Losers Of June 26: AVEO, MBRX, SELB, NEOT, SGEN...",2017-06-26 21:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oNN7yD2Dx8o/gainers--losers-of-june-26-aveo-mbrx-selb-neot-sgen-20170626-01211,"Gainers & Losers Of June 26: AVEO, MBRX, SELB, NEOT, SGEN..."
SGEN,SGEN:UW,BBG000BH0SG0,"Why Frontier Communications, Seattle Genetics, and Arconic Slumped Today",2017-06-26 20:57:59 +0000,http://finance.yahoo.com/r/72591901-2b06-347a-b0c9-b3ce62de6ca8/why-frontier-communications-seattle-genetics-and-a.aspx?yptr=yahoo&.tsrc=rss,These stocks dropped despite a mostly flat market. Find out why.
SGEN,SGEN:UW,BBG000BH0SG0,"Why Stratasys, Ltd. (SSYS), Arconic Inc (ARNC) and Seattle Genetics, Inc. (SGEN) Are 3 of Today’s Worst Stocks",2017-06-26 20:36:47 +0000,https://finance.yahoo.com/news/why-stratasys-ltd-ssys-arconic-203647751.html?.tsrc=rss,"It could have been worse though — you could have owned Stratasys, Ltd. (NASDAQ:SSYS), Arconic Inc (NYSE:ARNC) and Seattle Genetics, Inc. (NASDAQ:SGEN).  Seattle Genetics shareholders got the new trading week started on the wrong foot, with SGEN sliding 8.4% following reports that one of its cancer drug trials didn’t quite live up to expectations.  The drug, called Adcetris, was being co-developed by Japanese biopharma outfit Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) as a therapy for certain forms of blood cancer."
SGEN,SGEN:UW,BBG000BH0SG0,Biotech Rally Stumbles As These Small Caps Pull Back,2017-06-26 20:10:29 +0000,http://finance.yahoo.com/r/b1b5d241-6fbd-30fa-a171-a557b73d86dd/biotech-rally-stumbles-as-these-small-caps-pull-back?src=A00220&yptr=yahoo&.tsrc=rss,"Agios stock toppled Monday, two days after the biotech unveiled disappointing data for its drug, enasidenib, in patients with a blood cancer."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics: A Disappointing Study…Or Was It?,2017-06-26 18:52:00 +0000,http://finance.yahoo.com/r/6af3866f-8299-3e70-b1cc-b4d07210c8ee/seattle-genetics-a-disappointing-studyor-was-it-1498503146?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress.  The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint.  Altogether, lots of uncertainty whether these data could support a robust commercial adoption."
SGEN,SGEN:UW,BBG000BH0SG0,"Why Shares of Seattle Genetics, Inc. Got Whacked Today",2017-06-26 18:51:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6cHZwt2sTLk/why-shares-of-seattle-genetics-inc-got-whacked-today-cm808260,What happened Seattle Genetics NASDAQ SGEN 160 stock is down 8 7 as of 1 02 p m after the company announced 160 positive phase 3 data from its ECHELON 1 trial testing Adcetris as a first line treatment for Hodgkin lymphoma So what You read that right Shares are
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Enters Oversold Territory (SGEN),2017-06-26 17:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZmC77Yre5jQ/seattle-genetics-enters-oversold-territory-sgen-cm808204,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
SGEN,SGEN:UW,BBG000BH0SG0,"Mid-Day Update: U.S. Stocks Mixed as Oil Supply Worries Linger, Data Weakens",2017-06-26 17:29:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_HCZ5gUf4C8/mid-day-update-us-stocks-mixed-as-oil-supply-worries-linger-data-weakens-cm808239,U S stocks were mixed around mid session as investors remain worried about an oil supply gut and amid weak data U S stocks were mixed around mid session as investors remain worried about an oil supply gut and amid weak data Although oil prices were just higher again at mid day concerns
SGEN,SGEN:UW,BBG000BH0SG0,"Why Shares of Seattle Genetics, Inc. Got Whacked Today",2017-06-26 17:13:13 +0000,http://finance.yahoo.com/r/0bb1fa27-2d0e-30ec-b4ad-4b7bfed0d879/why-shares-of-seattle-genetics-inc-got-whacked-tod.aspx?yptr=yahoo&.tsrc=rss,Sometimes good news isn&apos;t good enough.
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics slumps as cancer drug data fails to impress,2017-06-26 16:36:02 +0000,https://finance.yahoo.com/news/seattle-genetics-slumps-cancer-drug-163602208.html?.tsrc=rss,"Seattle Genetics Inc's lymphoma  drug met the main goal in a late stage study, but shares of the  company tumbled as the data fell short of investor expectations  on the treatment's advantages over standard of care.  The drug, Adcetris, co-developed with Japan's Takeda  Pharmaceutical Co Ltd, met the goal of helping blood  cancer patients live longer without worsening their condition."
SGEN,SGEN:UW,BBG000BH0SG0,Story Stocks from Briefing.com,2017-06-26 16:14:00 +0000,https://finance.yahoo.com/news/story-stocks-briefing-com-175403381.html?.tsrc=rss,Story Stocks from Briefing.com
SGEN,SGEN:UW,BBG000BH0SG0,"J.P. Morgan Gives Thoughts on Seattle Genetics, Inc. (SGEN) Following Phase 3 Results",2017-06-26 15:18:33 +0000,https://finance.yahoo.com/news/j-p-morgan-gives-thoughts-151833555.html?.tsrc=rss,"Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) are tumbling nearly 10% in Monday's trading session, after the drug maker announced topline data from its ECHELON-1 Phase 3 study evaluating 1,334 patients with previously untreated patients with classical Hodgkin's lymphoma. The reason? The median progression-free survival (mPFS) benefit was not significant and modest overall response (OS) may temper enthusiasm."
SGEN,SGEN:UW,BBG000BH0SG0,"UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors",2017-06-26 13:57:03 +0000,https://finance.yahoo.com/news/seattle-genetics-takeda-lymphoma-drug-135529052.html?.tsrc=rss,"Seattle Genetics Inc and  Japan's Takeda Pharmaceutical Co Ltd said on Monday  that their drug met the main goal in a late-stage study of  helping blood cancer patients live longer without their  condition worsening.  The study testing the combination as an initial treatment  for advanced Hodgkin's lymphoma showed 82.1 percent lower risk  of cancer progression in patients, compared with 77.2 percent in  the control arm.  The control arm used standard-of-care chemotherapy, ABVD,  which combines adriamycin, bleomycin, vinblastine and  dacarbazine drugs."
SGEN,SGEN:UW,BBG000BH0SG0,"Pre-Market Most Active for Jun 26, 2017 :  AZN, VRX, MU, SGEN, P, QQQ, BAC, USLV, FB, CB, AAPL, TSM",2017-06-26 12:59:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/90T4d9KLvdg/pre-market-most-active-for-jun-26-2017-azn-vrx-mu-sgen-p-qqq-bac-uslv-fb-cb-aapl-tsm-cm807949,The NASDAQ 100 Pre Market Indicator is up 21 37 to 5 824 48 The total Pre Market volume is currently 3 636 063 shares traded The following are the most active stocks for the pre market session Astrazeneca PLC AZN is 0 36 at 35 43 with 451 394 shares traded AZN
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial",2017-06-26 12:07:22 +0000,https://finance.yahoo.com/news/seattle-genetics-takeda-lymphoma-drug-105854604.html?.tsrc=rss,"Seattle Genetics Inc and  Japan's Takeda Pharmaceutical Co Ltd said on Monday  that their drug met the main goal in a late-stage study of  helping blood cancer patients live longer without their  condition worsening.  The study tested Adcetris in combination with a three-drug  chemotherapy regimen, AVD, compared with standard of care, to  treat advanced Hodgkin's lymphoma in 1,334 patients who have had  no prior treatments.  Adcetris is already approved in the United States to treat  patients with classical Hodgkin's lymphoma, who have already  received a stem cell transplant or two chemotherapy treatments."
SGEN,SGEN:UW,BBG000BH0SG0,Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma,2017-06-26 10:45:00 +0000,https://finance.yahoo.com/news/takeda-seattle-genetics-announce-positive-104500799.html?.tsrc=rss,"Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival versus the control arm."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma,2017-06-26 10:45:00 +0000,http://finance.yahoo.com/r/0f1aa88a-b414-3d57-8e73-deed4707de60/seattle-genetics-drug-scratches-out-win-in-hodkin-lymphoma?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"In a closely watched result, Adcentris, a cancer drug sold by the biotech firm Seattle Genetics and the Japanese drug giant Takeda, outperformed traditional chemotherapy in front-line Hodgkin lymphoma, a result that is likely to lead to a broadened approval from the Food and Drug Administration."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Plunges After Issuing Stage 3 Trial Results,2017-06-26 09:34:00 +0000,http://finance.yahoo.com/r/6317d52f-ff83-35dd-889f-fb9bb32c62c8/seattle-genetics-plunges-after-issuing-stage-3-trial-results?src=A00220&yptr=yahoo&.tsrc=rss,Investors are not reacting favorably to the Seattle Genetics&apos; stage three trial results for its lymphoma treatment.
SGEN,SGEN:UW,BBG000BH0SG0,"Takeda, Seattle Genetics Report Positive Results From Phase 3 ECHELON-1 Trial",2017-06-26 07:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dL4KPh2uyZA/takeda-seattle-genetics-report-positive-results-from-phase-3-echelon1-trial-20170626-00255,"Takeda, Seattle Genetics Report Positive Results From Phase 3 ECHELON-1 Trial"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug,2017-06-21 17:23:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p_jH4NPyhLM/seattle-genetics-sgen-submits-bla-to-fda-for-cancer-drug-cm806384,Seattle Genetics Inc SGEN announced that it has submitted a supplemental Biologics License Application sBLA to the FDA for Adcetris brentuximab vedotin in patients with cutaneous T cell lymphoma CTCL In fact Adcetris is the only marketed product at Seattle Genetics The drug
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug,2017-06-21 15:08:03 +0000,https://finance.yahoo.com/news/seattle-genetics-sgen-submits-bla-150803337.html?.tsrc=rss,"Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL)."
SGEN,SGEN:UW,BBG000BH0SG0,"Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt",2017-06-21 12:30:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-clovis-soars-123012666.html?.tsrc=rss,"Key highlights in the biotech sector include positive data on Clovis&apos; (CLVS) PARP inhibitor, Rubraca."
SGEN,SGEN:UW,BBG000BH0SG0,Adcetris-Opdivo Combination for Classical Hodgkin Lymphoma,2017-06-21 11:36:50 +0000,http://finance.yahoo.com/r/d00231af-7efc-366e-ad31-959952a81077/adcetris-opdivo-combination-classical-hodgkin-lymphoma?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb and Seattle Genetics are evaluating the Adcetris-Opdivo combination to treat patients with relapsed classical Hodgkin Lymphoma.
SGEN,SGEN:UW,BBG000BH0SG0,Updates on the Adcetris and Opdivo Combination,2017-06-20 19:36:10 +0000,http://finance.yahoo.com/r/d1dfdee6-b40d-3a1a-8523-e64daa81bf20/updates-adcetris-opdivo-combination?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Halts Phase III Study on Leukemia Drug,2017-06-20 16:23:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9R5Bmd8zEac/seattle-genetics-halts-phase-iii-study-on-leukemia-drug-cm805683,Seattle Genetics Inc SGEN announced that it will discontinue the phase III study CASCADE o vadastuximab talirine SGN CD33A in frontline older acute myeloid leukemia AML patients The company took this decision after consulting the Independent Data Monitoring Committee IDMC and after
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Halts Phase III Study on Leukemia Drug,2017-06-20 14:31:02 +0000,https://finance.yahoo.com/news/seattle-genetics-halts-phase-iii-143102686.html?.tsrc=rss,"Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma,2017-06-20 12:00:00 +0000,https://finance.yahoo.com/news/seattle-genetics-submits-supplemental-biologics-120000633.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration based on data from the phase 3 ALCANZA trial and two phase 2 investigator-sponsored trials of ADCETRIS in patients with cutaneous T-cell lymphoma ."
SGEN,SGEN:UW,BBG000BH0SG0,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade",2017-06-20 02:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mVef7veM52A/amgns-xgeva-to-face-fda-in-feb-double-treat-for-lpcn-sgen-drops-cascade-20170620-00069,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade"
SGEN,SGEN:UW,BBG000BH0SG0,"Apple, PerkinElmer rise; EQT, Seattle Genetics fall",2017-06-19 21:21:33 +0000,https://finance.yahoo.com/news/apple-perkinelmer-rise-eqt-seattle-212133384.html?.tsrc=rss,"Stocks that moved substantially or traded heavily Monday: PerkinElmer Inc., up $4.16 to $67.73 The company, which sells testing equipment and scientific instruments, agreed to buy Euroimmun Medical Laboratory ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 06/19/2017: PKI,NVDQ,SYK,SGEN",2017-06-19 20:39:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gyfRBbDMErU/health-care-sector-update-for-06192017-pkinvdqsyksgen-cm805344,Top Health Care StocksTop Health Care Stocks JNJ 0 23 JNJ 0 23 PFE 0 70 PFE 0 70 ABT 1 37 ABT 1 37 MRK 1 12 MRK 1 12 AMGN 1 64 AMGN 1 64 Health care stocks were putting up strong gains to start the new week with the NYSE Health Care Index adding more than 0 8 in value today
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Dives To Low After Leukemia Drug Tied To Deaths,2017-06-19 20:17:24 +0000,http://finance.yahoo.com/r/127a678d-92df-3de7-93ee-323b8c7c2819/seattle-genetics-dives-to-5-month-low-after-leukemia-drug-tied-to-deaths?src=A00220&yptr=yahoo&.tsrc=rss,Seattle Genetics stock toppled to a five-month low Monday after announcing its leukemia drug was tied to deaths in a late-stage trial.
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 06/19/2017: CLVS,NVDQ,SYK,SGEN",2017-06-19 19:19:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EU3Eo6IYs54/health-care-sector-update-for-06192017-clvsnvdqsyksgen-cm805297,Top Health Care StocksTop Health Care Stocks JNJ 0 36 JNJ 0 36 PFE 0 82 PFE 0 82 ABT 1 53 ABT 1 53 MRK 1 27 MRK 1 27 AMGN 1 43 AMGN 1 43 Health care stocks were putting up strong gains to start the new week with the NYSE Health Care Index adding more than 0 8 while shares of
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205,2017-06-19 17:20:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZeoxO2hx_y8/bristol-myers-opdivo-positive-in-phase-ii-study-checkmate-205-cm805171,Bristol Myers Squibb Company BMY announced an extended follow up data on immuno oncology drug Opdivo The data from ongoing phase II study CheckMate 205 evaluated adult patients with classical Hodgkin lymphoma cHL who have failed autologous stem cell transplant ASCT irrespective
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics: Good News On The Horizon?,2017-06-19 17:12:00 +0000,http://finance.yahoo.com/r/cd070220-d2be-36aa-ab9e-b314d691346a/seattle-genetics-good-news-on-the-horizon-1497892356?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Is it time to buy shares of Seattle Genetics (SGEN)?  Seattle’s stock price fell 3% to $62.57 in recent market action after earlier dropping as much as 11% to an intraday low of $57.40 a share after the drug maker discontinued late-stage trials of an experimental leukemia drug after an independent data report showed a higher rate of deaths in the test group.  Needham analyst Chad Messer advised investors to “buy on weakness.” Granted, the loss of the company's second-most advanced pipeline program is “certainly bad news,” but data is coming later this year from the pivotal Echelon-1 study of Adcetris as a front-line treatment for HL."
SGEN,SGEN:UW,BBG000BH0SG0,Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For $6.7B,2017-06-19 15:39:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oWbWKAU0Qoc/mid-morning-market-update-markets-open-higher-eqt-to-buy-rice-energy-for-67b-cm805159,Following the market opening Monday the Dow traded up 0 50 percent to 21 492 11 while the NASDAQ climbed 1 245 percent to 6 228 43 The S amp P also rose gaining 0 70 percent to 2 450 13 Leading and Lagging Sectors Technology shares rose by 1 48 percent in the US market on
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Climbs Well Off Worst Levels But Remains Firmly Negative,2017-06-19 15:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y8sj5e-rxAk/seattle-genetics-climbs-well-off-worst-levels-but-remains-firmly-negative-20170619-01033,Seattle Genetics Climbs Well Off Worst Levels But Remains Firmly Negative
SGEN,SGEN:UW,BBG000BH0SG0,Clovis surges on positive cancer-drug data,2017-06-19 14:37:00 +0000,https://finance.yahoo.com/video/clovis-surges-positive-cancer-drug-143700598.html?.tsrc=rss,CNBC's Meg Tirrell reports the latest biotech and health care news including Clovis Oncology's new ovarian cancer drug study sending shares up.
SGEN,SGEN:UW,BBG000BH0SG0,"Biotech Movers: Clovis, Seattle Genetics, Rigel",2017-06-19 13:08:00 +0000,http://finance.yahoo.com/r/36fd8f41-9c38-3614-8c87-8d503013cdd2/biotech-movers-clovis-seattle-genetics-rigel.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics halts late-stage study of leukemia drug,2017-06-19 12:36:28 +0000,https://finance.yahoo.com/news/seattle-genetics-halts-stage-study-114446390.html?.tsrc=rss,"U.S. drug developer Seattle Genetics Inc  said on Monday it would halt a late-stage study of its  drug to treat a type of leukemia in old patients, after seeing a  ""higher rate"" of deaths in patients taking the drug compared to  those on a placebo.  Shares of Seattle Genetics fell 14 percent to $55.50 in  premarket trading.  The drug, vadastuximab talirine, was being evaluated in the  study to treat a form of blood cancer called acute myeloid  leukemia (AML)."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics suspends trial of leukemia treatment after data showed higher rate of death,2017-06-19 11:33:01 +0000,https://finance.yahoo.com/news/seattle-genetics-suspends-trial-leukemia-113301033.html?.tsrc=rss,"Seattle Genetics Inc. said Monday that it is discontinuing the Phase 3 clinical trial of its acute myeloid leukemia treatment, SGN-CD33A, after data indicated a higher rate of deaths, including fatal infections. ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics suspends trial of leukemia treatment after data showed higher rate of death,2017-06-19 11:33:01 +0000,http://finance.yahoo.com/r/2df3ef4e-c17b-3566-8628-268256bef3be/Story.aspx?guid=B26A43B7-9A6F-4BF6-A55F-BA119EC5DE2B&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Seattle Genetics Inc. said Monday that it is discontinuing the Phase 3 clinical trial of its acute myeloid leukemia treatment, SGN-CD33A, after data indicated a higher rate of deaths, including fatal infections. ..."
SGEN,SGEN:UW,BBG000BH0SG0,InPlay from Briefing.com,2017-06-19 10:56:10 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia,2017-06-19 10:45:00 +0000,https://finance.yahoo.com/news/seattle-genetics-discontinues-phase-3-104500048.html?.tsrc=rss,"Seattle Genetics, Inc. , a global biotechnology company, today announced that it is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine in frontline older acute myeloid leukemia patients."
SGEN,SGEN:UW,BBG000BH0SG0,Stocks May Benefit From Strength Overseas - U.S. Commentary,2017-06-19 08:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tyct4XQAJuQ/stocks-may-benefit-from-strength-overseas--us-commentary-20170619-00555,Stocks May Benefit From Strength Overseas - U.S. Commentary
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Discontinues Phase 3 CASCADE Trial In Frontline AML,2017-06-19 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5LoXna6PbQc/seattle-genetics-discontinues-phase-3-cascade-trial-in-frontline-aml-20170619-00302,Seattle Genetics Discontinues Phase 3 CASCADE Trial In Frontline AML
SGEN,SGEN:UW,BBG000BH0SG0,"Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ...",2017-06-17 19:18:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nJ8GTrEIjno/baker-bros-advisors-lp-buys-incyte-corp-avexis-inc-la-jolla-pharmaceutical-co-sells-abbvie-cm804758,Baker Bros Advisors Lp New Purchases ANAB JNCE TNXP BPMX WINT Added Positions INCY AVXS LJPC ASND AQXP HRTX BCRX CBAY DERM SGMO Reduced Positions ARRY EXEL ZGNX VSAR AGLE CRBP JUNO NTRA PRTO Sold Out ABBV DSCI ADHD ENTA
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 06/16/2017: SGEN,CLSN,IDXG",2017-06-16 20:18:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PO8FtGAHbSk/health-care-sector-update-for-06162017-sgenclsnidxg-cm804583,Top Health Care StocksTop Health Care Stocks JNJ 0 94 JNJ 0 94 PFE 0 30 PFE 0 30 ABT 0 17 ABT 0 17 MRK 0 32 MRK 0 32 AMGN 1 05 AMGN 1 05 Health care stocks were maintaining small gains Friday with the NYSE Health Care Index posting a nearly 0 4 advance while shares of health
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma,2017-06-15 10:58:00 +0000,https://finance.yahoo.com/news/seattle-genetics-bristol-myers-squibb-105800129.html?.tsrc=rss,"Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS and Opdivo in relapsed or refractory classical Hodgkin lymphoma at the International Conference on Malignant Lymphoma in Lugano, Switzerland."
SGEN,SGEN:UW,BBG000BH0SG0,"Gainers & Losers Of June 12: GTXI, XBIT, NDRM, CHRS, ZYNE...",2017-06-12 22:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H9y447yclsg/gainers--losers-of-june-12-gtxi-xbit-ndrm-chrs-zyne-20170612-01194,"Gainers & Losers Of June 12: GTXI, XBIT, NDRM, CHRS, ZYNE..."
SGEN,SGEN:UW,BBG000BH0SG0,Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct,2017-06-09 17:19:00 +0000,http://finance.yahoo.com/r/b10e95aa-fbb3-3685-928e-c858930e98cc/apple-could-hit-200-fast-if-this-breakout-setup-triggers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Huge profits could be on the doorstep for these hot breakout setups.
SGEN,SGEN:UW,BBG000BH0SG0,Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma,2017-06-07 12:00:00 +0000,https://finance.yahoo.com/news/takeda-seattle-genetics-announce-lancet-120000886.html?.tsrc=rss,"Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that data from the randomized Phase 3 ALCANZA clinical trial evaluating ADCETRIS in patients with cutaneous T-cell lymphoma were published in the journal Lancet."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Updated Results on Cancer Drug,2017-06-07 00:16:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KfZyu4YU_h4/seattle-genetics-reports-updated-results-on-cancer-drug-cm799730,Seattle Genetics Inc SGEN and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin ASG 22ME The candidate was assessed as monotherapy treatment for metastatic urothelial cancer mUC Enfortumab vedotin is an investigational antibody drug conjugate ADC
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Updated Results on Cancer Drug,2017-06-06 22:08:10 +0000,https://finance.yahoo.com/news/seattle-genetics-reports-updated-results-220810733.html?.tsrc=rss,"Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME)."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : June 6, 2017",2017-06-06 16:00:17 +0000,http://finance.yahoo.com/r/a95140a9-6345-33f1-a5a6-39bb6ba81d95/seattle-genetics-inc-value-analysis-nasdaqsgen-june-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Seattle Genetics, Inc. a score of 31. Our analysis is based on comparing Seattle Genetics, Inc. with the following peers – ImmunoGen, Inc., Biogen Inc., Celgene Corporation, Celldex Therapeutics, Inc., Pfizer Inc., GlaxoSmithKline plc Sponsored ADR, Spectrum Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Progenics Pharmaceuticals, Inc. and AbbVie, ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo,2017-06-05 23:01:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yTj6QAVOWsE/bristol-myers-presents-data-on-immuno-oncology-drug-opdivo-cm799033,Bristol Myers Squibb Company BMY announced that the European Commission EC has approved immuno oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma mUC in adults after failure of prior platinum containing therapy Opdivo is approved
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo,2017-06-05 20:29:08 +0000,https://finance.yahoo.com/news/bristol-myers-presents-data-immuno-202908298.html?.tsrc=rss,Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
SGEN,SGEN:UW,BBG000BH0SG0,InPlay from Briefing.com,2017-06-05 14:50:25 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Astellas Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting,2017-06-05 14:45:00 +0000,https://finance.yahoo.com/news/seattle-genetics-astellas-announce-updated-144500470.html?.tsrc=rss,"Seattle Genetics, Inc. and Astellas today highlighted updated phase 1 data for enfortumab vedotin studied as monotherapy treatment for metastatic urothelial cancer in an oral presentation at the American Society of Clinical Oncology 52nd Annual Meeting in Chicago."
SGEN,SGEN:UW,BBG000BH0SG0,Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting,2017-06-05 14:45:00 +0000,https://finance.yahoo.com/news/astellas-seattle-genetics-announce-updated-144500716.html?.tsrc=rss,"CHICAGO, June 5, 2017 /PRNewswire/ -- Astellas and Seattle Genetics, Inc. (SGEN) today highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral presentation at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.  Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein expressed in multiple solid tumors including mUC, ovarian cancer, and non-small cell lung cancer (NSCLC).  Based on the data from the ongoing phase 1 clinical trial, the companies this year plan to initiate a registrational monotherapy phase 2 trial for locally advanced or mUC patients who have been previously treated with checkpoint inhibitor (CPI) therapy."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : June 5, 2017",2017-06-05 12:43:13 +0000,http://finance.yahoo.com/r/439c68c9-858e-3d26-917c-228d8c48aa82/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-june-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma,2017-06-02 10:00:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-seattle-genetics-100000534.html?.tsrc=rss,"Bristol-Myers Squibb Company and Seattle Genetics, Inc. announced that the companies have entered into a collaboration agreement to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo and Seattle Genetics’ antibody-drug conjugate ADCETRIS in a pivotal phase 3 clinical trial."
SGEN,SGEN:UW,BBG000BH0SG0,Wall Street Aims High At Opening,2017-06-02 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EkbyDPGNCAc/wall-street-aims-high-at-opening-20170602-00237,Wall Street Aims High At Opening
SGEN,SGEN:UW,BBG000BH0SG0,Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS,2017-06-02 06:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pu3lkbYQBlE/bristolmyers--seattle-genetics-to-evaluate-combination-of-opdivo-and-adcetris-20170602-00174,Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS
SGEN,SGEN:UW,BBG000BH0SG0,"ETFs with exposure to Seattle Genetics, Inc. : May 30, 2017",2017-05-30 16:42:34 +0000,http://finance.yahoo.com/r/9b45c671-da9a-3cff-9e43-28f672f3320a/etfs-with-exposure-to-seattle-genetics-inc-may-30-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Commit To Purchase Seattle Genetics At $50, Earn 10.6% Annualized Using Options",2017-05-26 17:32:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ztzZ8V2WTJU/commit-to-purchase-seattle-genetics-at-50-earn-106-annualized-using-options-cm795408,Investors eyeing a purchase of Seattle Genetics Inc Symbol SGEN stock but cautious about paying the going market price of 66 44 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the December
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 19, 2017",2017-05-19 12:18:01 +0000,http://finance.yahoo.com/r/08636279-72b9-3710-862e-ff1f0e1cc42d/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-may-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. (SGEN) Leads 10 Notable Investor Filings",2017-05-19 02:11:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NYuBajpbY-g/seattle-genetics-inc-sgen-leads-10-notable-investor-filings-cm791655,InvestorPlace Stock Market News Stock Advice amp Trading Tips When a person or group of persons acquires beneficial ownership of more than 5 of a company s equity securities they are required to file a Schedule 13D or 13G with the SEC If these groups intend
SGEN,SGEN:UW,BBG000BH0SG0,Company Spotlight: Immunomedics,2017-05-12 07:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NcCMHfSX-gk/company-spotlight-immunomedics-20170512-00250,Company Spotlight: Immunomedics
SGEN,SGEN:UW,BBG000BH0SG0,"ImmunoGen, Inc. Begins FORWARD I, Investors Wait",2017-05-10 21:03:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sgs5TldyoyE/immunogen-inc-begins-forward-i-investors-wait-cm787491,ImmunoGen NASDAQ IMGN released first quarter earnings on Friday but with the lack of revenue from drugs on the market the focus was on the company s pipeline ImmunoGen results The only number that really matters
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference,2017-05-09 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-present-bank-america-120000905.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16 at 9:20 a.m. Pacific Time."
SGEN,SGEN:UW,BBG000BH0SG0,The Head-Scratching Reason Immunomedics Rose by as Much as 12%,2017-05-08 23:01:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Omt3A2EJZTY/the-head-scratching-reason-immunomedics-rose-by-as-much-as-12-cm786201,What happened Shares of Immunomedics NASDAQ IMMU a clinical stage drug developer focused on proprietary monoclonal antibody based therapies designed to fight cancer surged as much as 12 on Monday following a business update on Friday that saw a controversial licensing
SGEN,SGEN:UW,BBG000BH0SG0,The Head-Scratching Reason Immunomedics Rose by as Much as 12%,2017-05-08 21:53:00 +0000,http://finance.yahoo.com/r/5a869e6c-2196-3d68-ae7d-95458259f75b/the-head-scratching-reason-immunomedics-rose-by-as.aspx?yptr=yahoo&.tsrc=rss,Optimism surrounding its terminated licensing pact with Seattle Genetics sends shares soaring for a second straight day.
SGEN,SGEN:UW,BBG000BH0SG0,"Immunomedics Breaks Out, But Will It Last?",2017-05-08 10:00:00 +0000,http://finance.yahoo.com/r/36ad1849-08c6-34f8-baa4-70638a8e2d7e/immunomedics-breaks-out-will-it-last-immu-sgen?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Immunomedics rose about 20% on Friday after announcing some big changes, but will the trend higher continue over the coming week?"
SGEN,SGEN:UW,BBG000BH0SG0,"TXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch",2017-05-07 12:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mtsNKh07O2g/txmd-all-set-for-dday-immu-soars-on-strategic-plan-ctso-on-watch-20170507-00007,"TXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch"
SGEN,SGEN:UW,BBG000BH0SG0,Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?,2017-05-06 13:10:41 +0000,http://finance.yahoo.com/news/did-immunomedics-rise-too-much-131041914.html?.tsrc=rss,Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, MercadoLibre, and Pearson Jumped Today",2017-05-05 22:26:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PU9CADgrXkU/why-immunomedics-mercadolibre-and-pearson-jumped-today-cm785325,Friday was a solid day on Wall Street as major market benchmarks all posted modest advances to end the week on a positive note Investors still had some worries including this weekend s runoff election in France but strong numbers on the U S employment front and a rebound in the
SGEN,SGEN:UW,BBG000BH0SG0,"Immunomedics, Seattle Genetics Scrap License Deal",2017-05-05 20:32:00 +0000,http://finance.yahoo.com/r/2d89fb9b-a01f-36d3-b4c9-93e9c1e6d25c/immunomedics-seattle-genetics-scrap-license-deal.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics."
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 05/05/2017: RGLS,IMMU,SGEN,APHB",2017-05-05 20:24:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tcG6SnAesnc/health-care-sector-update-for-05052017-rglsimmusgenaphb-cm785252,Top Health Care StocksTop Health Care Stocks JNJ 0 47 JNJ 0 47 PFE 0 03 PFE 0 03 MRK 0 77 MRK 0 77 ABT 0 02 ABT 0 02 AMGN 0 42 AMGN 0 42 Health care stocks still were mostly lower with the NYSE Health Care Index recently sinking less than 0 1 while shares of health care
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Rocketed Today",2017-05-05 19:27:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tIbIckwC6vc/why-immunomedics-inc-rocketed-today-cm785171,What happened Immunomedics NASDAQ IMMU is up 18 at 1 11 p m EDT after announcing a new plan to develop sacituzumab govitecan on its own a capital raise and management stepping down So what In February Immunomedics licensed sacituzumab govitecan which also goes by
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 05/05/2017: FLDM,IMMU,APHB",2017-05-05 18:04:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vSKr7ktVtzs/health-care-sector-update-for-05052017-fldmimmuaphb-cm785159,Top Health Care StocksTop Health Care Stocks JNJ 0 61 JNJ 0 61 PFE 0 49 PFE 0 49 AVT 0 10 AVT 0 10 MRK 0 34 MRK 0 34 AMGN 1 09 AMGN 1 09 Health care stocks were mostly lower with the NYSE Health Care Index recently sinking about 0 2 while shares of health care companies in
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Rocketed Today",2017-05-05 17:57:00 +0000,http://finance.yahoo.com/r/3dfb4f2b-a8ba-3594-96d8-4d51807d1545/why-immunomedics-inc-rocketed-today.aspx?yptr=yahoo&.tsrc=rss,The biotech has a new plan that investors seem to like.
SGEN,SGEN:UW,BBG000BH0SG0,Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated,2017-05-05 14:42:00 +0000,http://finance.yahoo.com/r/fe9b6d01-a4f4-302a-acfd-496712ab3e8a/biotech-movers-immunomedics-shares-jump-after-license-pact-with-seattle-genetics-is-terminated.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132),2017-05-05 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-terminates-license-agreement-120000658.html?.tsrc=rss,"Seattle Genetics, Inc. , a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc. for sacituzumab govitecan and settle the related litigation."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Terminates License Deal With Immunomedics For IMMU-132,2017-05-05 08:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ePXJIeYVfEc/seattle-genetics-terminates-license-deal-with-immunomedics-for-immu132-20170505-00443,Seattle Genetics Terminates License Deal With Immunomedics For IMMU-132
SGEN,SGEN:UW,BBG000BH0SG0,"ETFs with exposure to Seattle Genetics, Inc. : May 4, 2017",2017-05-04 20:19:30 +0000,http://finance.yahoo.com/r/2ab1eddc-f5ed-3b66-95db-0f6127694358/etfs-with-exposure-to-seattle-genetics-inc-may-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017",2017-05-03 15:14:49 +0000,http://finance.yahoo.com/r/31bd1ed6-7647-34c7-aac1-184fe7ecb38d/seattle-genetics-inc-sgen-us-earnings-analysis-q1-2017-by-the-numbers-may-3-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Seattle Genetics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Seattle Genetics, Inc. – Biogen Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR, Bristol-Myers Squibb Company and AbbVie, Inc. (BIIB-US, CELG-US, GSK-US, BMY-US and ABBV-US) that have also reported ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : May 3, 2017",2017-05-03 12:47:19 +0000,http://finance.yahoo.com/r/38fe617f-b588-3693-a3b2-ea46aeeec255/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-sgen-us-may-3-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. Earnings: Solid Quarter, but Investors Wait",2017-05-01 19:27:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/za3SgQcp6yw/seattle-genetics-inc-earnings-solid-quarter-but-investors-wait-cm782198,Seattle Genetics NASDAQ SGEN reported solid first quarter earnings on Thursday but the potential expansion of Adcetris into treating patients in other cancer settings and the development of the rest of the biotech s pipeline are what investors are mainly focused on Seattle
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. Earnings: Solid Quarter, but Investors Wait",2017-05-01 18:00:00 +0000,http://finance.yahoo.com/r/494a0c90-2ce4-3694-bc86-47cb75b73a0b/seattle-genetics-inc-earnings-solid-quarter-but-in.aspx?yptr=yahoo&.tsrc=rss,Value-driving events won&apos;t come until the second half of the year or beyond.
SGEN,SGEN:UW,BBG000BH0SG0,Edited Transcript of SGEN earnings conference call or presentation 27-Apr-17 8:30pm GMT,2017-04-30 23:55:58 +0000,http://finance.yahoo.com/news/edited-transcript-sgen-earnings-conference-015730269.html?.tsrc=rss,Q1 2017 Seattle Genetics Inc Earnings Call
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates",2017-04-28 16:31:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-Kv2-s9LIhs/seattle-genetics-sgen-q1-loss-widens-sales-top-estimates-cm781260,Seattle Genetics Inc SGEN reported a loss of 42 cents per share for the first quarter of 2017 wider than the Zacks Consensus Estimate of a loss of 41 cents and the year ago loss of 15 cents per share Revenues came in at 109 1 million down 1 8 year over year primarily due to lower
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates",2017-04-28 13:57:01 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-q1-loss-135701278.html?.tsrc=rss,"Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 1Q loss,2017-04-27 20:04:59 +0000,http://finance.yahoo.com/news/seattle-genetics-reports-1q-loss-200459894.html?.tsrc=rss,"On a per-share basis, the Bothell, Washington-based company said it had a loss of 42 cents. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports First Quarter 2017 Financial Results,2017-04-27 20:02:00 +0000,http://finance.yahoo.com/news/seattle-genetics-reports-first-quarter-200200805.html?.tsrc=rss,"Seattle Genetics, Inc. , a global biotechnology company, today reported financial results for the first quarter ended March 31, 2017. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, vadastuximab talirine and enfortumab vedotin activities, as well as progress with its pipeline of antibody-drug conjugates and other proprietary programs."
SGEN,SGEN:UW,BBG000BH0SG0,"Investor Network: Seattle Genetics, Inc. to Host Earnings Call",2017-04-27 15:40:00 +0000,http://finance.yahoo.com/news/investor-network-seattle-genetics-inc-154000558.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 27, 2017 / Seattle Genetics, Inc. (NASDAQ: SGEN) will be discussing their earnings results in their Q1 Earnings Call to be held April 27, 2017 at 4:30 PM Eastern Time. ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Got Hammered Today",2017-04-22 00:02:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3X3VaKGtQXk/why-immunomedics-inc-got-hammered-today-cm777403,What happened Immunomedics NASDAQ IMMU fell 13 today after The Fly reported that Immunomedics told an Jefferies analyst that the biotech won t report data for its cancer drug sacituzumab govitecan which also goes by the code name IMMU 132 at the American Society of
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Got Hammered Today",2017-04-21 22:52:00 +0000,http://finance.yahoo.com/r/51495443-754a-3b08-a7e4-0464cf65ba04/why-immunomedics-inc-got-hammered-today.aspx?yptr=yahoo&.tsrc=rss,Sometimes it&apos;s what a company doesn&apos;t do that matters.
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : April 14, 2017",2017-04-14 12:05:29 +0000,http://finance.yahoo.com/r/02987baa-4b22-3f80-ba18-0423b41e9374/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-april-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017",2017-04-06 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-host-conference-call-120000047.html?.tsrc=rss,"Seattle Genetics, Inc. announced today that it will report its first quarter financial results on Thursday, April 27, 2017, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update."
SGEN,SGEN:UW,BBG000BH0SG0,New Strong Sell Stocks for April 3rd,2017-04-03 16:38:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JL8Ys10lZpY/new-strong-sell-stocks-for-april-3rd-cm769108,Here are 5 stocks added to the Zacks Rank 5 Strong Sell List today Accelerize Inc ACLZ provides software solutions for businesses to enhance their digital advertising The Zacks Consensus Estimate for its current year earnings has been revised 100 downward over the last 30
SGEN,SGEN:UW,BBG000BH0SG0,New Strong Sell Stocks for April 3rd,2017-04-03 14:06:02 +0000,http://finance.yahoo.com/news/strong-sell-stocks-april-3rd-140602669.html?.tsrc=rss,Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
SGEN,SGEN:UW,BBG000BH0SG0,New Strong Sell Stocks for April 3rd,2017-04-03 14:06:02 +0000,http://finance.yahoo.com/news/strong-sell-stocks-april-3rd-140602669.html,New Strong Sell Stocks for April 3rd
SGEN,SGEN:UW,BBG000BH0SG0,8:02 am Seattle Genetics will present data on its advancing antibody-drug conjugate and immuno-oncology programs at the 2017 AACR Meeting; will present Preclinical data evaluating the ability of brentuximab vedotin to induce immunogenic cel,2017-04-03 12:02:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#sgen,8:02 am Seattle Genetics will present data on its advancing antibody-drug conjugate and immuno-oncology programs at the 2017 AACR Meeting; will present Preclinical data evaluating the ability of brentuximab vedotin to induce immunogenic cel
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting,2017-04-03 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-presents-data-advancing-120000518.html?.tsrc=rss,"Seattle Genetics, Inc. , a global biotechnology company, today highlighted multiple data presentations that support the company’s advancing antibody-drug conjugate and immuno-oncology programs at the upcoming 108th Annual Meeting of the American Association for Cancer Research being held April 1-5, 2017, in Washington, D.C."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting,2017-04-03 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-presents-data-advancing-120000518.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today highlighted multiple data presentations that support the company’s advancing antibody-drug conjugate and immuno-oncology programs at the upcoming 108th Annual Meeting of the American Association for Cancer Research being held April 1-5, 2017, in Washington, D.C."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting,2017-03-30 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-highlights-leadership-antibody-120000282.html?.tsrc=rss,"Seattle Genetics, Inc. , a global biotechnology company, today announced its broad presence at the upcoming 108th Annual Meeting of the American Association for Cancer Research being held April 1 to 5, 2017, in Washington, D.C., including 14 presentations on antibody-drug conjugate and immuno-oncology technology advances and development programs."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting,2017-03-30 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-highlights-leadership-antibody-120000282.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today announced its broad presence at the upcoming 108th Annual Meeting of the American Association for Cancer Research being held April 1 to 5, 2017, in Washington, D.C., including 14 presentations on antibody-drug conjugate and immuno-oncology technology advances and development programs."
SGEN,SGEN:UW,BBG000BH0SG0,Battle in the Boardroom: What's Next for Immunomedics,2017-03-28 20:00:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U2cXMz1roTs/battle-in-the-boardroom-whats-next-for-immunomedics-cm766849,Shareholders of small cap biotech Immunomedics NASDAQ IMMU have been through a rollercoaster ride so far in 2017 Activist hedge fund VenBio has been stirring the pot over a perceived shameful deal between Immunomedics and Seattle Genetics NASDAQ SGEN So as the
SGEN,SGEN:UW,BBG000BH0SG0,Battle in the Boardroom: What's Next for Immunomedics,2017-03-28 18:06:00 +0000,https://www.fool.com/investing/2017/03/28/battle-in-the-boardroom-whats-next-for-immunomedic.aspx,Battle in the Boardroom: What's Next for Immunomedics
SGEN,SGEN:UW,BBG000BH0SG0,Battle in the Boardroom: What's Next for Immunomedics,2017-03-28 18:06:00 +0000,http://finance.yahoo.com/r/d26471d1-ff73-3c42-a4a2-e0241c3a6dd8/battle-in-the-boardroom-whats-next-for-immunomedic.aspx?yptr=yahoo&.tsrc=rss,Will VenBio successfully negotiate a higher bid for IMMU-132?
SGEN,SGEN:UW,BBG000BH0SG0,Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017,2017-03-28 14:00:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FTFbF9CSV_0/why-shares-of-immunomedics-inc-are-up-an-astounding-89-in-2017-cm766347,Shareholders of small cap biotech Immunomedics NASDAQ IMMU have had an absolutely blowout 2017 with shares up over 89 in the first 4 months of this year alone The combination of a shareholder activist along with a potential licensing deal has pushed share prices to highs
SGEN,SGEN:UW,BBG000BH0SG0,Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017,2017-03-28 12:26:00 +0000,http://finance.yahoo.com/r/5fb2f04f-6130-3021-9a80-4366a6ec51d5/why-shares-of-immunomedics-inc-are-up-an-astoundin.aspx?yptr=yahoo&.tsrc=rss,Will shares move higher? Or will a boardroom battle leave this biotech cruising for a bruising?
SGEN,SGEN:UW,BBG000BH0SG0,Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017,2017-03-28 12:26:00 +0000,https://www.fool.com/investing/2017/03/28/why-shares-of-immunomedics-inc-are-up-an-astoundin.aspx,Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : March 23, 2017",2017-03-23 12:06:04 +0000,http://finance.yahoo.com/r/76c58310-76ec-384e-af2e-703ece310cec/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-march-23-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seattle Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : March 23, 2017",2017-03-23 12:06:04 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-march-23-2017/,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : March 23, 2017"
SGEN,SGEN:UW,BBG000BH0SG0,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 21:09:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZGJWbPLlDBU/billionaires-best-healthcare-stock-picks-of-2017-so-far-cm763781,Billionaire investors didn t amass their fortunes by picking horrible stocks While you wouldn t want to blindly copy these successful investors it certainly doesn t hurt to watch which stocks they choose and how those stocks perform I looked at the portfolios of several of
SGEN,SGEN:UW,BBG000BH0SG0,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 19:02:00 +0000,http://finance.yahoo.com/r/9f08b028-c429-393a-9ff5-1ffec2af0934/billionaires-best-healthcare-stock-picks-of-2017-s.aspx?yptr=yahoo&.tsrc=rss,"Why billionaire investors are loving Immunomedics, Achaogen, AveXis, Exact Sciences, and Clovis Oncology this year."
SGEN,SGEN:UW,BBG000BH0SG0,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 19:02:00 +0000,https://www.fool.com/investing/2017/03/21/billionaires-best-healthcare-stock-picks-of-2017-s.aspx,Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
SGEN,SGEN:UW,BBG000BH0SG0,Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs,2017-03-17 18:06:00 +0000,http://finance.yahoo.com/r/f7cc9f3b-b472-3380-9764-3e463ce8e288/take-advantage-of-donald-trumps-tweets-to-buy-top-biotechs?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Everytime Donald Trump tweets about drug prices, biotech stocks take it on the chin. Bruce Pile believes these episodes are giving informed investors good entry points for some of the best names in biotech."
SGEN,SGEN:UW,BBG000BH0SG0,Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs,2017-03-17 18:06:00 +0000,http://www.forbes.com/sites/kenkam/2017/03/17/take-advantage-of-donald-trumps-tweets-to-buy-top-biotechs/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs
SGEN,SGEN:UW,BBG000BH0SG0,Coverage initiated on Seattle Genetics by Oppenheimer,2017-03-16 11:36:59 +0000,http://finance.yahoo.com/q/ud?s=SGEN,Coverage initiated on Seattle Genetics by Oppenheimer
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics To Participate In Barclays Healthcare Conference At 10:45 AM ET,2017-03-15 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/olBowtih9NE/seattle-genetics-to-participate-in-barclays-healthcare-conference-at-1045-am-et-20170315-00670,Seattle Genetics To Participate In Barclays Healthcare Conference At 10:45 AM ET
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?,2017-03-14 10:05:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XLBwqRhgdgk/seattle-genetics-sgen-up-82-since-earnings-report-can-it-continue-cm760304,It has been about a month since the last earnings report for Seattle Genetics Inc SGEN Shares have added about 8 2 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?,2017-03-14 07:53:07 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-8-2-075307913.html,Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?,2017-03-14 07:53:07 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-8-2-075307913.html?.tsrc=rss,Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-03-11 22:39:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-223900031.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 11, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-03-11 22:39:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-223900031.html?.tsrc=rss,"LOS ANGELES, CA / ACCESSWIRE / March 11, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline - SGEN,2017-03-11 01:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-010000208.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 10, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (""Seattle Genetics"" or the ""Company"") (NASDAQ: ..."
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline - SGEN,2017-03-11 01:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-010000208.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / March 10, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (""Seattle Genetics"" or the ""Company"") (NASDAQ: ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)",2017-03-10 19:25:00 +0000,http://www.investopedia.com/news/judge-blocks-2b-immunomedicsseattle-genetics-deal-immusgen/?partner=YahooSA,"Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)"
SGEN,SGEN:UW,BBG000BH0SG0,"Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)",2017-03-10 19:25:00 +0000,http://finance.yahoo.com/r/fdcf67f3-2aff-3595-95ca-610dd0548cd2/judge-blocks-2b-immunomedicsseattle-genetics-deal-immusgen?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Immunomedics stock hits 52-week high as judge blocks $2 billion deal, and market expects better valuation for the key drug"
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-03-10 15:47:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-154700575.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 10, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-03-10 15:47:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-154700575.html?.tsrc=rss,"LOS ANGELES, CA / ACCESSWIRE / March 10, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm",2017-03-10 15:30:00 +0000,http://finance.yahoo.com/news/march-13-deadline-alert-law-153000806.html?.tsrc=rss,"Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise acquired Seattle Genetics, Inc."
SGEN,SGEN:UW,BBG000BH0SG0,"March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm",2017-03-10 15:30:00 +0000,http://finance.yahoo.com/news/march-13-deadline-alert-law-153000806.html,"[Business Wire] - Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise acquired Seattle Genetics, Inc."
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN",2017-03-10 14:00:00 +0000,http://finance.yahoo.com/news/deadline-monday-levi-korsinsky-llp-140000816.html,"[PR Newswire] - NEW YORK, March 10, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics ..."
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN",2017-03-10 14:00:00 +0000,http://finance.yahoo.com/news/deadline-monday-levi-korsinsky-llp-140000816.html?.tsrc=rss,"NEW YORK, March 10, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events",2017-03-10 12:32:30 +0000,http://biz.yahoo.com/e/170310/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events"
SGEN,SGEN:UW,BBG000BH0SG0,"Why Marathon Oil, Signet Jewelers, and Immunomedics Jumped Today",2017-03-09 23:14:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MnwMyWG-Sbg/why-marathon-oil-signet-jewelers-and-immunomedics-jumped-today-cm758898,Thursday marked the eighth anniversary of the beginning of the current bull market in stocks Back in 2009 investors thought that the financial crisis might result in the end of financial markets worldwide but instead stocks bounced back and major market benchmarks have since tripled
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Jumped Higher Today",2017-03-09 23:14:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ys088Wj9GiE/why-immunomedics-inc-jumped-higher-today-cm758896,What happened Immunomedics NASDAQ IMMU ended the day up 19 5 after a judge ruled that the biotech can t close its deal with Seattle Genetics NASDAQ SGEN quite yet So what The stock price going up after the deal was temporarily blocked may seem
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted,2017-03-09 23:13:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vPr_RnM2iPU/immunomedics-immu-stock-soars-after-deal-with-seattle-genetics-is-halted-cm758873,Immunomedics Inc IMMU stock soared in midday trading Thursday following the stop on the company s deal with Seattle Genetics SGEN after the lawsuit filed by Immunomedics largest investor venBio Select Advisor LLC reported by The Street Immunomedics is up 16 4 at 5 85 per
SGEN,SGEN:UW,BBG000BH0SG0,"Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM...",2017-03-09 22:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MXg1EYtqzFA/gainers--losers-of-mar9-cbay-immu-tgtx-nspr-tndm-20170309-01447,"Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM..."
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Jumped Higher Today",2017-03-09 21:39:00 +0000,http://finance.yahoo.com/r/78ce2864-5dbc-3a6e-a9a1-54a4b05ece10/why-immunomedics-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,Investors are hoping for a better deal for IMMU-132.
SGEN,SGEN:UW,BBG000BH0SG0,"Why Immunomedics, Inc. Jumped Higher Today",2017-03-09 21:39:00 +0000,http://www.fool.com/investing/2017/03/09/why-immunomedics-inc-jumped-higher-today.aspx,"Why Immunomedics, Inc. Jumped Higher Today"
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted,2017-03-09 21:24:09 +0000,http://finance.yahoo.com/news/immunomedics-immu-stock-soars-deal-212409979.html,Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted,2017-03-09 21:24:09 +0000,http://finance.yahoo.com/news/immunomedics-immu-stock-soars-deal-212409979.html?.tsrc=rss,"Immunomedics, Inc. (IMMU) stock soared in midday trading Thursday following the stop on the company's deal with Seattle Genetics (SGEN) after the lawsuit filed by Immunomedics' largest investor, venBio Select Advisor LLC, reported by The Street."
SGEN,SGEN:UW,BBG000BH0SG0,Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold,2017-03-09 19:35:07 +0000,http://www.bizjournals.com/seattle/news/2017/03/09/seattle-genetics-immunomedics-deal-on-hold.html?ana=yahoo,Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold
SGEN,SGEN:UW,BBG000BH0SG0,Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold,2017-03-09 19:35:07 +0000,http://finance.yahoo.com/r/39cb2dc6-c64e-3cda-8d7d-9b4431324e3a/seattle-genetics-immunomedics-deal-on-hold.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Seattle Genetics Inc.'s $2 billion licensing deal is on hold after a Delaware judge ruled that Immunomedics Inc. can't close the deal amidst a struggle for control of its board.  Bothell-based Seattle Genetics signed the deal last month to purchase worldwide licensing rights to a cancer drug known as IMMU-132 from Immunomedics (IMMU).  A judge in the Delaware Court of Chancery ruled Immunomedics can't close on the solid tumor drug deal while a fight over the New Jersey company's board continues, according to Seattle Genetics (SGEN)."
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Soars on Injunction Against Seattle Genetics Deal,2017-03-09 18:33:00 +0000,http://finance.yahoo.com/r/42862d63-e1cd-30cf-8854-f5cbebd44584/immunomedics-soars-on-injunction-against-seattle-genetics-deal.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Soars on Injunction Against Seattle Genetics Deal,2017-03-09 18:33:00 +0000,https://www.thestreet.com/story/14035306/1/immunomedics-soars-on-injunction-against-seattle-genetics-deal.html?puc=yahoo&cm_ven=YAHOO,Immunomedics Soars on Injunction Against Seattle Genetics Deal
SGEN,SGEN:UW,BBG000BH0SG0,"Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against Seattle Genetics, Inc.",2017-03-09 15:30:00 +0000,http://finance.yahoo.com/news/investor-alert-gpm-reminds-investors-153000091.html,"[Business Wire] - Glancy Prongay & Murray LLP reminds investors of the March 13, 2017 deadline to file a lead plaintiff motion in the class action filed by GPM on behalf of a class of investors who purchased Seattle Genetics, Inc."
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017",2017-03-09 15:10:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151000640.html,"[GlobeNewswire] - NEW YORK, March 09, 2017-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. and certain of its officers, ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug,2017-03-09 00:13:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TWj9nQ333CA/seattle-genetics-sgen-fda-lifts-hold-on-trial-of-aml-drug-cm758238,Seattle Genetics Inc SGEN announced that the FDA has lifted the clinical hold on two phase I trials of its candidate vadastuximab talirine SGN CD33A 33A 160 Vadastuximab talirine is an early stage candidate that is being developed for the treatment of acute myeloid leukemia AML
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug,2017-03-08 21:55:09 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-fda-lifts-215509004.html,Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN",2017-03-08 16:57:24 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-165724329.html,"[GlobeNewswire] - NEW YORK, March 08, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. between ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics resumes two leukemia trials, ends one after FDA lifts hold",2017-03-07 23:15:09 +0000,http://www.bizjournals.com/seattle/blog/health-care-inc/2017/03/seattle-genetics-resumes-two-leukemia-trials-ends.html?ana=yahoo,"Seattle Genetics resumes two leukemia trials, ends one after FDA lifts hold"
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-03-06 16:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-160000146.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 6, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to resume trials as FDA lifts clinical hold,2017-03-06 12:48:57 +0000,http://finance.yahoo.com/news/seattle-genetics-resume-trials-fda-124857015.html,"[Reuters] - Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug. The FDA imposed the clinical hold in December after the company reported the deaths of four people in trials testing the experimental cancer drug, vadastuximab talirine. Seattle Genetics said on Monday the clinical hold was resolved through a comprehensive study evaluating more than 300 patients and amendments to further enhance safety."
SGEN,SGEN:UW,BBG000BH0SG0,FDA lifts hold on Seattle Genetics drug trials,2017-03-06 12:03:09 +0000,http://finance.yahoo.com/news/fda-lifts-hold-seattle-genetics-120309520.html,[Reuters] - Seattle Genetics Inc said on Monday the U.S. Food and Drug Administration had lifted the clinical hold on several early stage studies testing its experimental cancer drug. The FDA imposed the clinical ...
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-03-06 11:52:30 +0000,http://biz.yahoo.com/e/170306/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
SGEN,SGEN:UW,BBG000BH0SG0,FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine,2017-03-06 11:45:00 +0000,http://finance.yahoo.com/news/fda-lifts-clinical-hold-seattle-114500739.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today announced that the U.S. Food and Drug Administration has lifted the clinical hold announced on December 27, 2016 on phase 1 trials of vadastuximab talirine in acute myeloid leukemia ."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Says FDA Lifts Clinical Hold On Vadastuximab Talirine,2017-03-06 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yZ4mJwWn-D8/seattle-genetics-says-fda-lifts-clinical-hold-on-vadastuximab-talirine-20170306-00313,Seattle Genetics Says FDA Lifts Clinical Hold On Vadastuximab Talirine
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact The Firm",2017-03-05 14:00:00 +0000,http://finance.yahoo.com/news/deadline-alert-brower-piven-reminds-140000947.html,"[GlobeNewswire] - STEVENSON, Md., March 05, 2017-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
SGEN,SGEN:UW,BBG000BH0SG0,Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote,2017-03-03 17:21:00 +0000,https://www.thestreet.com/story/14026332/1/activist-investor-wins-control-of-immunomedics-board-following-shareholder-vote.html?puc=yahoo&cm_ven=YAHOO,Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Seattle Genetics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline",2017-03-03 16:32:00 +0000,http://finance.yahoo.com/news/shareholder-alert-faruqi-faruqi-llp-163200281.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 3, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Board Institutes Measures As Stockholder Fiduciaries To Preserve Their Best Business Judgment To Protect The Rights Of All Stockholders,2017-03-03 15:19:00 +0000,http://finance.yahoo.com/news/immunomedics-board-institutes-measures-stockholder-151900239.html,"[PR Newswire] - MORRIS PLAINS, N.J., March 3, 2017 /PRNewswire/ -- Immunomedics, Inc. (IMMU) (""Immunomedics"" or ""the Company"") today announced that on behalf of all stockholders, it will continue to pursue legally justified relief against venBio Select Advisor LLC (""venBio"") and venBio's four director candidates in the United States District Court for the District of Delaware (the ""Federal Action"") for their unlawful proxy fight that continues to violate a myriad of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017",2017-03-03 15:13:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151300504.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 3, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017",2017-03-03 14:31:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-143100708.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
SGEN,SGEN:UW,BBG000BH0SG0,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. -- SGEN,2017-03-02 23:34:00 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-233400140.html,"[PR Newswire] - NEW YORK, March 2, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc. securities (NASDAQ: ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Upcoming Investor Conferences,2017-03-01 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-present-upcoming-investor-130000059.html,"[Business Wire] - Seattle Genetics, Inc. announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section."
SGEN,SGEN:UW,BBG000BH0SG0,IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the Western District of Washington against Seattle Genetics Inc.,2017-02-28 23:00:00 +0000,http://finance.yahoo.com/news/important-seattle-genetics-inc-investor-230000594.html,"[GlobeNewswire] - NEW YORK, Feb. 28, 2017-- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. and certain of its officers. The class action, filed ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-28 01:47:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-014700798.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 27, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline – SGEN,2017-02-28 01:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-010000389.html,"[GlobeNewswire] - NEW YORK, Feb. 27, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. and certain of its officers. The class action, filed in United States District ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day",2017-02-27 16:52:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Iuq4gAkx84A/arch-coal-seattle-genetics-skyworks-solutions-texas-instruments-and-apple-highlighted-as-zacks-bull-and-bear-of-the-day-cm753623,For Immediate Release Chicago IL February 27 2017 Zacks Equity Research highlights 160 Arch Coal NYSE ARCH Free Report as the Bull of the Day Seattle Genetics NASDAQ SGEN Free Report as the Bear of the Day In addition Zacks Equity Research provides analysis
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-27 15:51:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-155100645.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 27, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017",2017-02-27 15:15:00 +0000,http://finance.yahoo.com/news/sgen-shareholder-alert-law-offices-151500879.html,[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.
SGEN,SGEN:UW,BBG000BH0SG0,"March 13, 2017 Deadline in Lawsuit for Investors in NASDAQ: SGEN Shares Against Seattle Genetics, Inc. Announced by Shareholders Foundation",2017-02-27 14:55:00 +0000,http://finance.yahoo.com/news/march-13-2017-deadline-lawsuit-145500166.html,"March 13, 2017 Deadline in Lawsuit for Investors in NASDAQ: SGEN Shares Against Seattle Genetics, Inc. Announced by Shareholders Foundation"
SGEN,SGEN:UW,BBG000BH0SG0,"Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day",2017-02-27 14:30:02 +0000,http://finance.yahoo.com/news/arch-coal-seattle-genetics-skyworks-143002969.html,"Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day"
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Issues Open Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation,2017-02-27 13:00:00 +0000,http://finance.yahoo.com/news/immunomedics-issues-open-letter-highlighting-130000769.html,"[GlobeNewswire] - Immunomedics Intends to Implement a Non-Dilutive, Lower Risk and Potentially Higher Reward Strategy that Considers the Interests of ALL Stockholders. Immunomedics’ Plan is Significantly Different from ..."
SGEN,SGEN:UW,BBG000BH0SG0,SEATTLE GENETICS INC /WA Financials,2017-02-25 18:04:13 +0000,http://finance.yahoo.com/q/is?s=sgen,SEATTLE GENETICS INC /WA Financials
SGEN,SGEN:UW,BBG000BH0SG0,3 Biotech Long Shots: Boom Or Bust?,2017-02-25 00:50:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e4VtaovgNro/3-biotech-long-shots-boom-or-bust-cm753149,The ability to develop game changing new drugs that revolutionize patient care could cause shares in Axovant Sciences NYSE AXON Celldex Therapeutics NASDAQ CLDX and Esperion Therapeutics NASDAQ ESPR to soar However success may be tough to come by and that
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-24 15:28:00 +0000,http://finance.yahoo.com/news/investor-notice-lundin-law-pc-152800242.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 24, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,Bear of the Day: Seattle Genetics (SGEN),2017-02-24 12:01:12 +0000,http://finance.yahoo.com/news/bear-day-seattle-genetics-sgen-120112907.html,Bear of the Day: Seattle Genetics (SGEN)
SGEN,SGEN:UW,BBG000BH0SG0,"Pawar Law Group Announces that a Securities Class Action Lawsuit has been filed Against Seattle Genetics, Inc. - SGEN",2017-02-24 04:48:00 +0000,http://finance.yahoo.com/news/pawar-law-group-announces-securities-044800056.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 23, 2017 / The Pawar Law Group announces a class action lawsuit on behalf of Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") (NASDAQ: ..."
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Sues Board Over Seattle Genetics Deal,2017-02-23 16:53:00 +0000,http://www.investopedia.com/news/immunomedics-sues-shareholders-amid-2b-deal-immu/?partner=YahooSA,Immunomedics Sues Board Over Seattle Genetics Deal
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-22 18:44:00 +0000,http://finance.yahoo.com/news/sgen-shareholder-alert-lundin-law-184400774.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 22, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,First Week of April 21st Options Trading For Seattle Genetics,2017-02-22 16:52:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kqTy7q6Rqjo/first-week-of-april-21st-options-trading-for-seattle-genetics-cm751433,Investors in Seattle Genetics Inc Symbol SGEN saw new options become available this week for the April 21st expiration At Stock Options Channel our YieldBoost formula has looked up and down the SGEN options chain for the new April 21st contracts and identified one put and one call
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017",2017-02-22 16:40:00 +0000,http://finance.yahoo.com/news/sgen-investor-alert-law-offices-164000262.html,"[PR Newswire] - NEW YORK, Feb. 22, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017",2017-02-22 15:14:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151400758.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 22, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report",2017-02-21 22:10:29 +0000,http://biz.yahoo.com/e/170221/sgen10-k.html,"SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report"
SGEN,SGEN:UW,BBG000BH0SG0,7 Stocks That Are Beating the Market,2017-02-21 21:01:10 +0000,http://finance.yahoo.com/news/7-stocks-beating-market-210110493.html,7 Stocks That Are Beating the Market
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer,2017-02-17 17:00:00 +0000,http://finance.yahoo.com/news/immunomedics-presents-updated-results-sacituzumab-170000493.html,"[GlobeNewswire] - Phase 2 Results Reported at 2017 Genitourinary Cancers Symposium. Objective Response Rate of 31%, One Confirmed Complete Response and Ten Confirmed Partial Responses. Median Progression-Free Survival of ..."
SGEN,SGEN:UW,BBG000BH0SG0,VenBio Tries to Block Immunomedics Cancer Deal,2017-02-17 16:21:00 +0000,http://www.investopedia.com/news/venbio-blocks-immunomedics-deal-immu-sgen/?partner=YahooSA,VenBio Tries to Block Immunomedics Cancer Deal
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-17 15:51:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-155100216.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 17, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN",2017-02-17 14:54:00 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-145400739.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat",2017-02-16 22:02:30 +0000,http://biz.yahoo.com/e/170216/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat"
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-15 23:37:00 +0000,http://finance.yahoo.com/news/sgen-investor-alert-lundin-law-233700376.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 15, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,SGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action – SGEN,2017-02-15 19:40:20 +0000,http://finance.yahoo.com/news/sgen-notice-rosen-law-firm-194020357.html,"[GlobeNewswire] - NEW YORK, Feb. 15, 2017-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Seattle Genetics Inc. securities from October 27, 2016 through December 23, 2016, inclusive of the important ..."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-15 16:38:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-163800412.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / February 15, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017",2017-02-15 15:07:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150700835.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 15, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data",2017-02-15 12:04:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-regenerons-praluent-120412057.html,"Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug,2017-02-15 01:55:08 +0000,http://www.bizjournals.com/seattle/blog/health-care-inc/2017/02/seattle-genetics-licensing-deal-immunomedics.html?ana=yahoo,Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-14 21:45:00 +0000,http://finance.yahoo.com/news/sgen-shareholder-alert-lundin-law-214500998.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 14, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm",2017-02-14 20:30:00 +0000,http://finance.yahoo.com/news/deadline-alert-brower-piven-alerts-203000049.html,"[Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Seattle Genetics Inc."
SGEN,SGEN:UW,BBG000BH0SG0,Activist Investor to Block Partnership of Immunomedics and Seattle Genetics,2017-02-14 17:33:00 +0000,http://www.thestreet.com/video/14001726/activist-investor-to-block-partnership-of-immunomedics-and-seattle-genetics.html?puc=yahoov&cm_ven=YAHOOV,Activist Investor to Block Partnership of Immunomedics and Seattle Genetics
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017",2017-02-14 17:23:15 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-sgen-us-earnings-analysis-2016-by-the-numbers-february-14-2017/,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017"
SGEN,SGEN:UW,BBG000BH0SG0,Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics,2017-02-14 15:56:00 +0000,https://www.thestreet.com/story/14000225/1/activist-investor-seeks-legal-block-of-immunomedics-cancer-drug-partnership-with-seattle-genetics.html?puc=yahoo&cm_ven=YAHOO,Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Earnings: Waiting on ECHELON,2017-02-14 06:55:46 +0000,http://www.fool.com/investing/2017/02/13/seattle-genetics-earnings-waiting-on-echelon.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Seattle Genetics Earnings: Waiting on ECHELON
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Earnings: Waiting on ECHELON,2017-02-13 22:18:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FpowRCgnUe4/seattle-genetics-earnings-waiting-on-echelon-cm747295,Seattle Genetics NASDAQ SGEN released fourth quarter earnings on Thursday and gave investors a taste of what s to come later this year With modest growth for Adcetris its only drug on the market investors should be focused on Seattle Genetics pipeline and clinical trials
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-13 19:45:00 +0000,http://finance.yahoo.com/news/important-equity-alert-khang-khang-194500111.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / February 13, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017",2017-02-13 18:30:00 +0000,http://finance.yahoo.com/news/sgen-shareholder-alert-law-offices-183000574.html,[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.
SGEN,SGEN:UW,BBG000BH0SG0,"Here’s Our Take On The Immunomedics, Inc. (IMMU) Deal",2017-02-13 15:30:35 +0000,http://www.insidermonkey.com/blog/heres-our-take-on-the-immunomedics-inc-immu-deal-546559/,"Here’s Our Take On The Immunomedics, Inc. (IMMU) Deal"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 13, 2017",2017-02-13 14:06:18 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-sgen-us-earnings-analysis-q4-2016-by-the-numbers-february-13-2017/,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 13, 2017"
SGEN,SGEN:UW,BBG000BH0SG0,Blog Coverage Immunomedics Announces a $2 Billion Cancer Deal with Seattle Genetics,2017-02-13 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-immunomedics-announces-2-131500872.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / February 13, 2017 / Active Wall St. blog coverage looks at the headline from Immunomedics Inc. (NASDAQ: IMMU ) and Seattle Genetics Inc. (NASDAQ: SGEN ). On February 10th, 2017, ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference,2017-02-13 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-present-leerink-partners-130000782.html,"[Business Wire] - Seattle Genetics, Inc. announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern Time."
SGEN,SGEN:UW,BBG000BH0SG0,"ICPT Catches Investors'' Eyes, TCON Abuzz, IMMU Inks $2Bln Deal With SGEN",2017-02-12 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y26yyMX3OUM/icpt-catches-investors-eyes-tcon-abuzz-immu-inks-2bln-deal-with-sgen-20170212-00110,"ICPT Catches Investors'' Eyes, TCON Abuzz, IMMU Inks $2Bln Deal With SGEN"
SGEN,SGEN:UW,BBG000BH0SG0,Will Seattle Genetics' Deal With Immunomedics Get Scuttled?,2017-02-12 21:17:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VOJO962Dscc/will-seattle-genetics-deal-with-immunomedics-get-scuttled-cm746783,Last week Seattle Genetics NASDAQ SGEN announced an agreement to license Immunomedics NASDAQ IMMU IMMU 132 a cancer drug that s already completed midstage phase 2 trials The deal could be a big win for Seattle Genetics but it doesn t have the full support
SGEN,SGEN:UW,BBG000BH0SG0,Will Seattle Genetics' Deal With Immunomedics Get Scuttled?,2017-02-12 20:01:06 +0000,http://www.fool.com/investing/2017/02/12/will-seattle-genetics-deal-with-immunomedics-get-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Will Seattle Genetics' Deal With Immunomedics Get Scuttled?
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline - SGEN,2017-02-11 01:05:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-010500705.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 10, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 02/10/2017: TCON,IMMU,SGEN,BSTG",2017-02-10 21:37:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AB6oIFvxaFA/health-care-sector-update-for-02102017-tconimmusgenbstg-cm746548,Top Health Care StocksTop Health Care Stocks JNJ 1 10 JNJ 1 10 PFE 0 12 PFE 0 12 MRK 0 46 MRK 0 46 ABT 0 33 ABT 0 33 AMGN 0 30 AMGN 0 30 Health care stocks were fighting to keep pace to the upside with most other sectors with the NYSE Health Care Index today rising about 0 2
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss",2017-02-10 21:18:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c6w2Iz6AHzM/seattle-genetics-sgen-loss-wider-than-expected-in-q4-revenues-miss-cm746517,Seattle Genetics Inc SGEN reported a loss of 39 cents per share wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year ago loss of 18 cents Revenues came in at 105 3 million up 12 6 year over year primarily on the back of strong sales of
SGEN,SGEN:UW,BBG000BH0SG0,Could Seattle Genetics' Adcetris Grab 'Blockbuster Status' After 2017 Trial?,2017-02-10 21:07:30 +0000,http://www.investors.com/news/technology/could-seattle-genetics-adcetris-grab-blockbuster-status-after-2017-trial/,Could Seattle Genetics' Adcetris Grab 'Blockbuster Status' After 2017 Trial?
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss",2017-02-10 19:15:07 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-loss-wider-191507280.html,"Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss"
SGEN,SGEN:UW,BBG000BH0SG0,Mid-Day Market Update: Infinera Surges On Earnings Beat; ChannelAdvisor Shares Plunge,2017-02-10 18:37:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CRNjAkRol8c/mid-day-market-update-infinera-surges-on-earnings-beat-channeladvisor-shares-plunge-cm746454,Midway through trading Friday the Dow traded up 0 43 percent to 20 258 28 while the NASDAQ gained 0 27 percent to 5 730 85 The S amp P also rose gaining 0 29 percent to 2 314 47 Leading and Lagging Sectors Basic materials shares climbed by 1 31 percent in trading on
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 02/10/2017: ONVO,IMMU,SGEN,BSTG",2017-02-10 18:37:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DVTdAUk2RKU/health-care-sector-update-for-02102017-onvoimmusgenbstg-cm746442,Top Health Care StocksTop Health Care Stocks JNJ 1 35 JNJ 1 35 PFE 0 06 PFE 0 06 MRK 0 47 MRK 0 47 ABT 0 22 ABT 0 22 AMGN 0 21 AMGN 0 21 Health care stocks were fighting to keep pace to the upside with most other sectors with the NYSE Health Care Index today rising about 0 3
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics 4Q Loss 39 Cents/Share Misses Street,2017-02-10 15:52:00 +0000,http://www.investopedia.com/news/seattle-genetics-q4-loss-misses-street-sgen/?partner=YahooSA,Seattle Genetics 4Q Loss 39 Cents/Share Misses Street
SGEN,SGEN:UW,BBG000BH0SG0,"Immunomedics, Seattle Genetics Ink $2B Cancer Deal",2017-02-10 15:05:00 +0000,http://www.investopedia.com/news/immunomedics-seattle-genetics-ink-2b-cancer-deal-immu-sgen/?partner=YahooSA,"Immunomedics, Seattle Genetics Ink $2B Cancer Deal"
SGEN,SGEN:UW,BBG000BH0SG0,"Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News",2017-02-10 14:14:00 +0000,https://www.thestreet.com/story/13997880/1/immunomedics-seattle-genetics-lead-biotech-movers-on-deal-news.html?puc=yahoo&cm_ven=YAHOO,"Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News"
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Announces Postponement of 2016 Annual Meeting,2017-02-10 12:26:00 +0000,http://finance.yahoo.com/news/immunomedics-announces-postponement-2016-annual-122600945.html,"[PR Newswire] - MORRIS PLAINS, N.J., Feb. 10, 2017 /PRNewswire/ -- Immunomedics, Inc. (IMMU) (""Immunomedics"" or ""the Company"") today announced it has postponed the Company's 2016 Annual Meeting of Stockholders previously scheduled for February 16, 2017. The Annual Meeting has been postponed to March 3, 2017 at 10:00 a.m. Eastern Time and will be held at the Executive Offices of Immunomedics, Inc., located at 300 The American Road, Morris Plains, New Jersey 07950. As announced in a separate press release today, Immunomedics has entered into an exclusive global licensing agreement with Seattle Genetics, Inc. (SGEN) an innovative global biotechnology company, in a transaction with potential payments of up to $2 billion, plus double-digit tiered royalties on global net sales."
SGEN,SGEN:UW,BBG000BH0SG0,"Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties",2017-02-10 11:50:00 +0000,http://finance.yahoo.com/news/immunomedics-enters-exclusive-global-licensing-115000584.html,"[PR Newswire] - MORRIS PLAINS, N.J., Feb. 10, 2017 /PRNewswire/ -- Immunomedics, Inc. (IMMU) (""Immunomedics"") today announced that it has entered into an exclusive global licensing agreement with Seattle Genetics, Inc. (SGEN), an innovative global biotechnology company that develops and commercializes novel antibody-drug conjugates (ADCs) for the treatment of cancer. Under the agreement, Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics' proprietary solid tumor therapy candidate. The agreement also provides that Seattle Genetics will be responsible for initiating the Phase 3 clinical trial of IMMU-132 in patients with metastatic triple-negative breast cancer (TNBC) and submitting the initial Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors",2017-02-10 11:49:00 +0000,http://uk.finance.yahoo.com/news/seattle-genetics-announces-global-license-114900013.html,"Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors"
SGEN,SGEN:UW,BBG000BH0SG0,Immunomedics Reaches Deal With Seattle Genetics For Sacituzumab Govitecan,2017-02-10 07:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gzntdVThe8o/immunomedics-reaches-deal-with-seattle-genetics-for-sacituzumab-govitecan-20170210-00303,Immunomedics Reaches Deal With Seattle Genetics For Sacituzumab Govitecan
SGEN,SGEN:UW,BBG000BH0SG0,Edited Transcript of SGEN earnings conference call or presentation 9-Feb-17 9:30pm GMT,2017-02-09 23:45:33 +0000,http://finance.yahoo.com/news/edited-transcript-sgen-earnings-conference-234533610.html,Edited Transcript of SGEN earnings conference call or presentation 9-Feb-17 9:30pm GMT
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 4Q loss,2017-02-09 22:19:29 +0000,http://sg.finance.yahoo.com/news/seattle-genetics-reports-4q-loss-221929791.html,Seattle Genetics reports 4Q loss
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today,2017-02-09 21:30:00 +0000,http://biz.yahoo.com/cc/2/155172.html,Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2017-02-09 21:17:45 +0000,http://biz.yahoo.com/e/170209/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results,2017-02-09 21:02:00 +0000,http://finance.yahoo.com/news/seattle-genetics-reports-fourth-quarter-210200316.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today reported financial results for the fourth quarter and year ended December 31, 2016. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, vadastuximab talirine and enfortumab vedotin activities, as well as progress with its pipeline of antibody-drug conjugates and other proprietary programs."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-09 20:40:00 +0000,http://finance.yahoo.com/news/sgen-investor-alert-lundin-law-204000049.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 9, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline",2017-02-09 20:23:00 +0000,http://finance.yahoo.com/news/shareholder-alert-faruqi-faruqi-llp-202300577.html,"[PR Newswire] - NEW YORK, Feb. 9, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") (SGEN) of the March 13, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the Western District of Washington on behalf of all those who purchased Seattle Genetics securities between October 27, 2016 and December 23, 2016 (the ""Class Period""). The case, Patel v. Seattle Genetics, Inc. et al, No. 2:17-cv-00041 was filed on January 10, 2017."
SGEN,SGEN:UW,BBG000BH0SG0,"After-Hours Earnings Report for February 9, 2017 :  NVDA, TRI, ATVI, CERN, EXPE, MHK, AGU, WU, SGEN, VRSN, ZAYO, CSL",2017-02-09 19:53:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Muydyg0awig/after-hours-earnings-report-for-february-9-2017-nvda-tri-atvi-cern-expe-mhk-agu-wu-sgen-vrsn-zayo-csl-cm745738,The following companies are expected to report earnings after hours on 02 09 2017 Visit our Earnings Calendar for a full list of expected earnings releases NVIDIA Corporation NVDA is reporting for the quarter ending January 31 2017 The
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Issues 2017 Revenue Guidance - Quick Facts,2017-02-09 17:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pPeSZPy4CJY/seattle-genetics-issues-2017-revenue-guidance--quick-facts-20170209-01763,Seattle Genetics Issues 2017 Revenue Guidance - Quick Facts
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Q4 16 Earnings Conference Call At 4:30 PM ET,2017-02-09 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f9YDOELfwNY/seattle-genetics-q4-16-earnings-conference-call-at-430-pm-et-20170209-01390,Seattle Genetics Q4 16 Earnings Conference Call At 4:30 PM ET
SGEN,SGEN:UW,BBG000BH0SG0,Q4 2016 Seattle Genetics Inc Earnings Release - After Market Close,2017-02-09 12:07:05 +0000,http://biz.yahoo.com/research/earncal/20170209.html?t=sgen,Q4 2016 Seattle Genetics Inc Earnings Release - After Market Close
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-08 21:39:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-213900192.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / February 8, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017",2017-02-08 18:28:29 +0000,http://finance.yahoo.com/news/sgen-investor-alert-law-offices-182829257.html,"[GlobeNewswire] - NEW YORK, Feb. 08, 2017-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-08 18:23:00 +0000,http://finance.yahoo.com/news/sgen-equity-alert-lundin-law-182300721.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 8, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017",2017-02-08 15:14:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151400957.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 8, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-04 01:54:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-khang-khang-015400007.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / February 3, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline - SGEN,2017-02-04 01:08:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-010800088.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 3, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-03 19:20:00 +0000,http://finance.yahoo.com/news/sgen-equity-notice-lundin-law-192000766.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 3, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",2017-02-03 18:03:38 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-encourages-180338437.html,"[GlobeNewswire] - STEVENSON, Md., Feb. 03, 2017-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN",2017-02-03 16:34:19 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-163419348.html,"[GlobeNewswire] - NEW YORK, Feb. 03, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. between ..."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-02 16:36:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-163600480.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / February 2, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017",2017-02-02 15:13:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151300619.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 2, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi",2017-02-01 22:21:17 +0000,http://biz.yahoo.com/e/170201/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi"
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-02-01 16:27:00 +0000,http://finance.yahoo.com/news/sgen-investor-notice-lundin-law-162700887.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 1, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Seattle Genetics, Inc. Investors and Encourages Investors to Contact the Firm",2017-02-01 15:30:00 +0000,http://finance.yahoo.com/news/law-offices-howard-g-smith-153000770.html,"[Business Wire] - Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Seattle Genetics, Inc. securities between October 27, 2016 and December 23, 2016, inclusive ."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-31 22:57:00 +0000,http://finance.yahoo.com/news/important-equity-alert-khang-khang-225700155.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / January 31, 2017 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. – SGEN,2017-01-31 19:19:28 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-191928366.html,"[GlobeNewswire] - NEW YORK, Jan. 31, 2017-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc. securities from October 27, ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-30 20:00:00 +0000,http://finance.yahoo.com/news/sgen-shareholder-alert-lundin-law-200000247.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Seattle Genetics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN",2017-01-30 15:31:00 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-153100374.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics ..."
SGEN,SGEN:UW,BBG000BH0SG0,3 Mid-Cap Biotech Stocks to Buy in February,2017-01-30 12:27:46 +0000,http://www.fool.com/investing/2017/01/29/3-mid-cap-biotech-stocks-to-buy-in-february.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Mid-Cap Biotech Stocks to Buy in February
SGEN,SGEN:UW,BBG000BH0SG0,3 Mid-Cap Biotech Stocks to Buy in February,2017-01-29 13:31:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yKUzag6Rxiw/3-mid-cap-biotech-stocks-to-buy-in-february-cm739849,Many small cap biotech stocks are super risky with no products on the market yet Some big cap biotech stocks on the other hand aren t growing like they used to Mid cap biotech stocks could meet Goldilocks criteria of finding what is just right Three mid cap biotechs in
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-28 03:39:00 +0000,http://finance.yahoo.com/news/sgen-shareholder-notice-lundin-law-033900696.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 27, 2017 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline – SGEN,2017-01-28 01:15:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-011500010.html,"[GlobeNewswire] - NEW YORK, Jan. 27, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. and certain of its officers. The class action, filed in United States District ..."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-27 17:35:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-173500149.html,"[Business Wire] - Khang & Khang LLP announces the filing of a class action lawsuit against Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Seattle Genetics, Inc. Investors and Encourages Investors to Contact the Firm",2017-01-27 15:30:00 +0000,http://finance.yahoo.com/news/glancy-prongay-murray-announces-filing-153000866.html,"[Business Wire] - Glancy Prongay & Murray LLP announces that a class action lawsuit has been filed on behalf of investors who purchased Seattle Genetics, Inc. securities between October 27, 2016 and December 23, 2016, inclusive ."
SGEN,SGEN:UW,BBG000BH0SG0,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017",2017-01-27 15:10:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151000345.html,"[GlobeNewswire] - NEW YORK, Jan. 27, 2017-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seattle Genetics, Inc. and certain of its officers, ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Lagoda Investment Management, L.P. Buys Texas Pacific Land Trust, Microsoft Corp, Coca-Cola Co, ...",2017-01-25 18:30:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p14cQdQb1H4/lagoda-investment-management-lp-buys-texas-pacific-land-trust-microsoft-corp-coca-cola-co-cm738196,Lagoda Investment Management L P New Purchases TPL MSFT KO JNJ BF B C GS ICE GLD LVS Added Positions VNRX ALXN BRK B MA XOM Y ESGR Reduced Positions SNMX BIDU SGEN MACK TTOO XON RNR GOOG PTC NVO Sold Out GSK New
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-24 22:28:00 +0000,http://finance.yahoo.com/news/important-equity-alert-lundin-law-222800670.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 24, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Seattle Genetics, Inc. Investors",2017-01-24 22:16:00 +0000,http://finance.yahoo.com/news/investor-alert-law-offices-howard-221600883.html,"[Business Wire] - Law Offices of Howard G. Smith announces an investigation on behalf of Seattle Genetics, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,Levi & Korsinsky Notifies Shareholders of a Complaint Filed in U.S. District Court to Recover Losses Suffered by Investors in Seattle Genetics (SGEN),2017-01-23 20:09:12 +0000,http://ir.baystreet.ca/article.aspx?id=427&1485202152,Levi & Korsinsky Notifies Shareholders of a Complaint Filed in U.S. District Court to Recover Losses Suffered by Investors in Seattle Genetics (SGEN)
SGEN,SGEN:UW,BBG000BH0SG0,5 Stupendously Expensive Cancer Drugs,2017-01-23 16:27:28 +0000,http://www.fool.com/investing/2017/01/23/5-stupendously-expensive-cancer-drugs.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Stupendously Expensive Cancer Drugs
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-23 15:00:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-150000928.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 23, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Lawsuit for Investors in shares of Seattle Genetics, Inc. (NASDAQ:SGEN) announced by Shareholders Foundation",2017-01-23 14:45:00 +0000,http://finance.yahoo.com/news/lawsuit-investors-shares-seattle-genetics-144500563.html,"[GlobeNewswire] - SAN DIEGO, Jan. 23, 2017-- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Washington on behalf of certain purchasers of shares of Seattle Genetics, Inc. over alleged Securities ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS (SGEN) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Seattle Genetics, Inc.; Encourages all Investors to Contact the Firm for Information",2017-01-21 18:01:00 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-alert-johnson-180100752.html,"[PR Newswire] - SAN DIEGO, Jan. 21, 2017 /PRNewswire/ -- Johnson & Weaver, LLP announces that a class action complaint was filed on behalf of purchasers of Seattle Genetics, Inc., (NASDAQ: SGEN) securities during the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-21 02:12:00 +0000,http://finance.yahoo.com/news/sgen-equity-alert-lundin-law-021200994.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 20, 2017 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Seattle Genetics Inc. and Certain Officers - SGEN,2017-01-21 01:15:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-011500471.html,"[PR Newswire] - NEW YORK, Jan. 20, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. (""Seattle Genetics"" or the ""Company"") (NASDAQ: SGEN) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 17-cv-00041, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, both dates inclusive (the ""Class Period""), seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. If you are a shareholder who purchased Seattle Genetics securities during the Class Period, you have until March 13, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-20 22:18:00 +0000,http://finance.yahoo.com/news/sgen-investor-alert-lundin-law-221800449.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 20, 2017 / Lundin Law PC , a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Robbins Arroyo LLP: Seattle Genetics, Inc. (SGEN) Misled Shareholders According to a Recently Filed Class Action",2017-01-20 21:40:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-seattle-genetics-214000896.html,"[Business Wire] - Shareholder rights law firm, Robbins Arroyo LLP, announces that a class action complaint was filed against Seattle Genetics, Inc. in the U.S. District Court for the Western District of Washington at Seattle."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",2017-01-20 19:18:00 +0000,http://finance.yahoo.com/news/investor-alert-brower-piven-encourages-191800215.html,"[Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Seattle Genetics Inc."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-20 17:36:00 +0000,http://finance.yahoo.com/news/sgen-investor-alert-lundin-law-173600719.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"Glancy Prongay & Murray LLP Commences Investigation on Behalf of Seattle Genetics, Inc. Investors",2017-01-20 15:30:00 +0000,http://finance.yahoo.com/news/glancy-prongay-murray-llp-commences-153000361.html,"[Business Wire] - Glancy Prongay & Murray LLP announces an investigation on behalf of Seattle Genetics, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-19 23:29:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-232900648.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 19, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,SEATTLE GENETICS INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Western District of Washington against Seattle Genetics Inc.,2017-01-19 22:26:19 +0000,http://finance.yahoo.com/news/seattle-genetics-inc-investor-alert-222619409.html,"[GlobeNewswire] - NEW YORK, Jan. 19, 2017-- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. and certain of its officers. The class action, filed ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Lifshitz & Miller Law Firm Announces Investigation of Ally Financial Inc., Amphastar Pharmaceuticals, Inc., Lannett Company, Inc., Live Ventures Incorporated, MiMedx Group, Inc., Seattle Genetics, Inc., Teligent, Inc., TerraVia Holdings, In",2017-01-19 20:03:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-200300519.html,"[PR Newswire] - NEW YORK, January 19, 2017 /PRNewswire/ -- Ally Financial Inc. (ALLY) Lifshitz & Miller announces investigation on behalf of ALLY investors concerning whether ALLY adequately disclosed information regarding ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Seattle Genetics, Inc. Investors",2017-01-19 19:39:00 +0000,http://finance.yahoo.com/news/investor-alert-law-offices-howard-193900076.html,"[Business Wire] - Law Offices of Howard G. Smith announces an investigation on behalf of investors of Seattle Genetics, Inc. concerning the Company and its officers’ potential violation of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-19 16:10:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-161000016.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 19, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017",2017-01-19 15:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151000528.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 19, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results on February 9, 2017",2017-01-19 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-host-conference-call-130000491.html,"[Business Wire] - Seattle Genetics, Inc. announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets."
SGEN,SGEN:UW,BBG000BH0SG0,5 Expensive Drugs That Could End Up in Trump's Crosshairs,2017-01-18 23:37:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oblDGAE3opo/5-expensive-drugs-that-could-end-up-in-trumps-crosshairs-cm735129,Donald Trump s taking aim at drug companies that have increasingly found themselves in the hot seat because of sky high drug price increases in the past Last week Trump likened the industry s history of price hikes as akin to getting away with murder and he hinted that
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-18 22:56:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-225600401.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 18, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,5 Expensive Drugs That Could End Up in Trump's Crosshairs,2017-01-18 21:41:08 +0000,http://www.fool.com/investing/2017/01/18/5-expensive-drugs-that-could-end-up-in-trumps-cros.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Expensive Drugs That Could End Up in Trump's Crosshairs
SGEN,SGEN:UW,BBG000BH0SG0,SGEN LOSS NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action,2017-01-18 19:39:00 +0000,http://finance.yahoo.com/news/sgen-loss-notice-rosen-law-193900976.html,"[Business Wire] - Rosen Law Firm, a global investor rights law firm, reminds purchasers of Seattle Genetics Inc. securities from October 27, 2016 through December 23, 2016, inclusive of the important March 13, 2017 lead plaintiff deadline in the class action."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Seattle Genetics, Inc. and Advises Investors With Losses to Contact the Firm",2017-01-17 20:39:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-goldberg-law-203900722.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is filing a class action lawsuit against Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT EQUITY ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-17 19:38:00 +0000,http://finance.yahoo.com/news/important-equity-alert-lundin-law-193800415.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 17, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017",2017-01-17 16:33:53 +0000,http://finance.yahoo.com/news/sgen-shareholder-alert-law-offices-163353993.html,"[GlobeNewswire] - NEW YORK, Jan. 17, 2017-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased ..."
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces a Class Action Lawsuit against Seattle Genetics, Inc. and Advises Investors with Losses to Contact the Firm",2017-01-13 16:34:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-goldberg-law-163400238.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is filing a class action lawsuit against Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017",2017-01-13 15:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151000176.html,"[GlobeNewswire] - NEW YORK, Jan. 13, 2017-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Seattle Genetics, Inc. and certain of its officers, ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER NOTICE: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-13 01:25:00 +0000,http://finance.yahoo.com/news/shareholder-notice-lundin-law-pc-012500104.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 12, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact Brower Piven Before The Lead Plaintiff Deadline",2017-01-13 01:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-notifies-010000924.html,"[GlobeNewswire] - STEVENSON, Md., Jan. 12, 2017-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
SGEN,SGEN:UW,BBG000BH0SG0,How Is Mylan’s Generics Segment Doing?,2017-01-12 14:08:04 +0000,http://marketrealist.com/2017/01/how-is-mylans-generics-segment-doing/?utm_source=yahoo&utm_medium=feed,How Is Mylan’s Generics Segment Doing?
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-11 22:36:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-223600382.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 11, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline",2017-01-11 21:22:00 +0000,http://finance.yahoo.com/news/shareholder-alert-faruqi-faruqi-llp-212200207.html,"[GlobeNewswire] - NEW YORK, Jan. 11, 2017-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. of the March 13, 2017 deadline to seek the role of lead plaintiff in ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017",2017-01-11 19:59:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-195900832.html,"[PR Newswire] - NEW YORK, Jan. 11, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Seattle Genetics, Inc. (""Seattle ..."
SGEN,SGEN:UW,BBG000BH0SG0,"INVESTOR ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2017-01-11 18:02:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-180200857.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 11, 2017 / Lundin Law PC , a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN",2017-01-11 16:47:39 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-164739821.html,"[GlobeNewswire] - NEW YORK, Jan. 11, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. between ..."
SGEN,SGEN:UW,BBG000BH0SG0,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. – SGEN,2017-01-11 16:03:00 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-160300324.html,"[Business Wire] - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc. securities from October 27, 2016 through December 23, 2016, inclusive ."
SGEN,SGEN:UW,BBG000BH0SG0,Pomerantz Law Firm Announces the Filing of a Class Action against Seattle Genetics Inc. and Certain Officers – SGEN,2017-01-11 15:12:50 +0000,http://finance.yahoo.com/news/pomerantz-law-firm-announces-filing-151250539.html,"[GlobeNewswire] - NEW YORK, Jan. 11, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Seattle Genetics Inc. and certain of its officers. The class action, filed in United States District ..."
SGEN,SGEN:UW,BBG000BH0SG0,"After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next",2017-01-10 18:52:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E305Mk4Dbx0/after-ariads-acquisition-these-3-cancer-drug-stocks-could-be-next-cm731788,Japanese drugmaker Takeda Pharmaceutical Company NASDAQOTH TKPYY 160 announced yesterday that it s acquiring ARIAD Pharmaceuticals NASDAQ ARIA 160 for 24 per share or 5 2 billion The deal removes yet another commercial stage cancer drugmaker from the market and
SGEN,SGEN:UW,BBG000BH0SG0,"After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next",2017-01-10 17:21:07 +0000,http://www.fool.com/investing/2017/01/10/3-cancer-stocks-that-could-be-next-to-get-acquired.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics To Present At J.P. Morgan Conference; Webcast At 5:30 PM ET,2017-01-09 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9k-TQNVm-bI/seattle-genetics-to-present-at-jp-morgan-conference-webcast-at-530-pm-et-20170109-00875,Seattle Genetics To Present At J.P. Morgan Conference; Webcast At 5:30 PM ET
SGEN,SGEN:UW,BBG000BH0SG0,Biotech Industry Off to a Strong Start in 2017 Latest Reports on Seattle Genetics and Ionis Pharmaceuticals,2017-01-09 14:15:00 +0000,http://finance.yahoo.com/news/biotech-industry-off-strong-start-141500460.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 9, 2017 / The Biotech Industry has had a strong start to the year after a rocky 2016. The iShares NASDAQ Biotechnology Index ETF ( IBB ) and the SPDR S&P Biotech ETF ..."
SGEN,SGEN:UW,BBG000BH0SG0,Friday’s 6 Biopharma Movers That Can’t Be Ignored,2017-01-06 16:55:34 +0000,http://finance.yahoo.com/news/friday-6-biopharma-movers-t-165534942.html,Friday’s 6 Biopharma Movers That Can’t Be Ignored
SGEN,SGEN:UW,BBG000BH0SG0,Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering,2017-01-05 13:15:00 +0000,http://finance.yahoo.com/news/post-earnings-coverage-ohr-pharma-131500062.html,"[Accesswire] - Upcoming AWS Coverage on Seattle Genetics Post-Earnings Results LONDON, UK / ACCESSWIRE / January 5, 2017 / Active Wall St. announces its post-earnings coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma,2017-01-05 13:14:10 +0000,http://www.publicnow.com/view/A3DBE310ABA6BC1D2832939D27CC6A1622DE389F,"[at noodls] - -SGN-CD352A, a Novel Antibody-Drug Conjugate (ADC), Represents Seattle Genetics' 9 Clinical Stage Program in a Robust Pipeline of Empowered Antibody Therapies- -Preclinical Data Showing Potent Antitumor ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma,2017-01-05 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-initiates-phase-1-130000693.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma ."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Seattle Genetics, Inc. (SGEN)",2017-01-04 15:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151900222.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 4, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Seattle Genetics, Inc. (""Seattle Genetics"" or the ..."
SGEN,SGEN:UW,BBG000BH0SG0,Forget Buffett — four unsung investment gurus are picking these eight stocks for 2017,2017-01-04 10:21:41 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=D4BF0A4E-D1C2-11E6-A00A-1DD92694FEDA&siteid=yhoof2,Forget Buffett — four unsung investment gurus are picking these eight stocks for 2017
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Seattle Genetics, Inc. and Advises Investors with Losses to Contact the Firm",2016-12-30 23:48:00 +0000,http://finance.yahoo.com/news/important-investor-alert-goldberg-law-234800158.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Seattle Genetics, Inc. - SGEN",2016-12-30 21:57:00 +0000,http://finance.yahoo.com/news/equity-alert-rosen-law-firm-215700576.html,"[Business Wire] - Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Seattle Genetics, Inc. resulting from allegations that Seattle Genetics may have issued materially misleading business information to the investing public."
SGEN,SGEN:UW,BBG000BH0SG0,Biotech Stocks: What to Watch in 2017,2016-12-30 21:22:32 +0000,http://www.fool.com/investing/2016/12/29/biotech-stocks-what-to-watch-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Stocks: What to Watch in 2017
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2016-12-30 17:40:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-174000159.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Seattle Genetics, Inc. - SGEN",2016-12-30 16:57:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-165700806.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 30, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") (NASDAQ: ..."
SGEN,SGEN:UW,BBG000BH0SG0,PRESS DIGEST - Wall Street Journal - Dec 30,2016-12-30 05:05:46 +0000,http://finance.yahoo.com/news/press-digest-wall-street-journal-050546023.html,[Reuters] - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Indian government officials will likely meet early next week ...
SGEN,SGEN:UW,BBG000BH0SG0,Biotech Stocks: What to Watch in 2017,2016-12-29 22:57:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r53fbZDbezo/biotech-stocks-what-to-watch-in-2017-cm727678,This year has been a little rocky for biotech stocks In fact it s on pace to be the first decline for the sector in quite a few years But despite this year s decline for the sector there are plenty of individual biotech stocks with potential catalysts to help them rocket higher in
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics CEO Angles For Hodgkin's Lymphoma Eureka: Exclusive,2016-12-29 22:15:07 +0000,http://www.investors.com/news/technology/seattle-genetics-ceo-angles-for-hodgkins-lymphoma-eureka-exclusive/,Seattle Genetics CEO Angles For Hodgkin's Lymphoma Eureka: Exclusive
SGEN,SGEN:UW,BBG000BH0SG0,[$$] Seattle Genetics Takes a Hit,2016-12-29 12:57:00 +0000,http://www.barrons.com/articles/seattle-genetics-takes-a-hit-1483016267?mod=yahoobarrons&ru=yahoo,[$$] Seattle Genetics Takes a Hit
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics Gets Price-Target Cut On FDA News, But Shares Up",2016-12-28 21:03:20 +0000,http://www.investors.com/news/technology/seattle-genetics-gets-price-target-cut-on-fda-news-but-shares-up/,"Seattle Genetics Gets Price-Target Cut On FDA News, But Shares Up"
SGEN,SGEN:UW,BBG000BH0SG0,"Four patients die in Seattle Genetics cancer trial, stock plummets",2016-12-28 17:44:36 +0000,http://www.bizjournals.com/seattle/blog/health-care-inc/2016/12/four-patients-die-in-seattle-genetics-cancer-trial.html?ana=yahoo,"Four patients die in Seattle Genetics cancer trial, stock plummets"
SGEN,SGEN:UW,BBG000BH0SG0,"IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Seattle Genetics, Inc. and Advises Investors with Losses to Contact the Firm",2016-12-28 16:22:00 +0000,http://finance.yahoo.com/news/important-investor-alert-goldberg-law-162200529.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Seattle Genetics, Inc. and Certain Officers and Directors",2016-12-28 15:52:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-155200089.html,"[Business Wire] - Levi & Korsinsky, LLP announces that it has commenced an investigation of Seattle Genetics, Inc. concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors."
SGEN,SGEN:UW,BBG000BH0SG0,2 Reasons Seattle Genetics' Clinical Holds Were A Surprise,2016-12-28 15:16:39 +0000,http://finance.yahoo.com/news/2-reasons-seattle-genetics-clinical-151639398.html,2 Reasons Seattle Genetics' Clinical Holds Were A Surprise
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Seattle Genetics, Inc. (SGEN)",2016-12-28 15:15:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151500649.html,"[PR Newswire] - NEW YORK, Dec. 28, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold",2016-12-28 15:02:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Jkz0UVgKkE/biotech-stock-roundup-fda-nod-for-biogenionis-drug-seattle-genetics-hit-by-clinical-hold-cm726791,Biogen BIIB and Ionis IONS got an early Christmas gift with the FDA approving their spinal muscular atrophy SMA treatment Spinraza three months within the filing of the regulatory application Meanwhile Seattle Genetics SGEN has been hit by clinical holds on several early stage
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold,2016-12-28 15:02:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oGhpDokTJ4A/seattle-genetics-acute-myeloid-leukemia-drug-on-fda-hold-cm726782,Shares of Seattle Genetics Inc SGEN plunged 15 4 after the FDA placed a full clinical hold on a phase I II study and a partial clinical hold on two phase I studies on vadastuximab talirine SGN CD33A following the death of four patients Note that Seattle Genetics year to date
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold,2016-12-28 12:52:12 +0000,http://finance.yahoo.com/news/seattle-genetics-acute-myeloid-leukemia-125212892.html,Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold
SGEN,SGEN:UW,BBG000BH0SG0,"Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold",2016-12-28 12:32:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-fda-nod-123212945.html,"Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold"
SGEN,SGEN:UW,BBG000BH0SG0,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths,2016-12-28 04:45:10 +0000,http://www.wsj.com/articles/seattle-genetics-cancer-drug-trials-on-hold-after-four-patient-deaths-1482846052?ru=yahoo?mod=yahoo_itp,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm",2016-12-28 03:10:00 +0000,http://finance.yahoo.com/news/seattle-genetics-notification-faruqi-faruqi-031000992.html,"[PR Newswire] - NEW YORK, Dec. 27, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Seattle Genetics, Inc. (""Seattle Genetics"" ..."
SGEN,SGEN:UW,BBG000BH0SG0,Biogen and Fitbit trade higher while Endologix tumbles,2016-12-28 02:07:25 +0000,http://sg.finance.yahoo.com/news/biogen-fitbit-trade-higher-while-020725510.html,Biogen and Fitbit trade higher while Endologix tumbles
SGEN,SGEN:UW,BBG000BH0SG0,What Happened in the Stock Market Today,2016-12-28 01:57:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BzvYODi4kFE/what-happened-in-the-stock-market-today-cm726709,Image source Getty Images Stocks ticked higher on Tuesday with the Dow Jones Industrial Average DJINDICES DJI 160 inching toward the 20 000 point mark and the S amp P 500 SNPINDEX GSPC adding slightly to its double digit gain for 2016 Today s stock
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",2016-12-28 00:55:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-005500365.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. concerning possible violations of federal securities laws."
SGEN,SGEN:UW,BBG000BH0SG0,"ANTH Plunges On Failed SOLUTION, All Eyes On CEMP, FDA Says No To AMPH Again",2016-12-28 00:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sLY7Jpr8M54/anth-plunges-on-failed-solution-all-eyes-on-cemp-fda-says-no-to-amph-again-20161228-00003,"ANTH Plunges On Failed SOLUTION, All Eyes On CEMP, FDA Says No To AMPH Again"
SGEN,SGEN:UW,BBG000BH0SG0,What Happened in the Stock Market Today,2016-12-27 23:59:00 +0000,http://www.fool.com/investing/2016/12/27/what-happened-in-the-stock-market-today.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,What Happened in the Stock Market Today
SGEN,SGEN:UW,BBG000BH0SG0,"Why Seattle Genetics, Inc. (SGEN), Endologix, Inc. (ELGX) and Amphastar Pharmaceuticals Inc (AMPH) Are 3 of Today’s Worst Stocks",2016-12-27 23:56:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PvLHjrR_Ak0/why-seattle-genetics-inc-sgen-endologix-inc-elgx-and-amphastar-pharmaceuticals-inc-amph-are-3-of-todays-worst-stocks-cm726696,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Feeling good on the first day back from a major holiday weekend and perhaps inspired by the strongest consumer confidence we ve seen since 2001 the market managed to get the new week
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics Leukemia Drug Trials Halted, Stock Plunges",2016-12-27 21:14:23 +0000,http://www.investors.com/news/technology/seattle-genetics-leukemia-drug-trials-halted-stock-plunges/,"Seattle Genetics Leukemia Drug Trials Halted, Stock Plunges"
SGEN,SGEN:UW,BBG000BH0SG0,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Seattle Genetics, Inc. - SGEN",2016-12-27 19:33:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-193300098.html,"[PR Newswire] - NEW YORK, Dec. 27, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Seattle Genetics, Inc. (""Seattle Genetics"" or the ""Company"") (NASDAQ: SGEN). ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 12/27/2016: SGEN,CAPN,ENGX",2016-12-27 18:57:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S56Zclgw56c/health-care-sector-update-for-12272016-sgencapnengx-cm726587,Top Health Care StocksTop Health Care Stocks JNJ 0 02 JNJ 0 02 PFE 0 46 PFE 0 46 MRK 0 62 MRK 0 62 ABT 0 81 ABT 0 81 AMGN 1 10 AMGN 1 10 Health care stocks were moderately higher with the NYSE Health Care Index climbing about 0 2 while shares of health care companies in the S amp
SGEN,SGEN:UW,BBG000BH0SG0,"Why Seattle Genetics, Inc. Got Clobbered Today",2016-12-27 18:57:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZiKI7nHu7t8/why-seattle-genetics-inc-got-clobbered-today-cm726564,Image source Getty Images What happened Seattle Genetics NASDAQ SGEN is down 15 at 11 57 a m EST after announcing the Food and Drug Administration has put a clinical hold on multiple early stage clinical trials testing its cancer drug vadastuximab talirine which used to
SGEN,SGEN:UW,BBG000BH0SG0,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths,2016-12-27 18:55:10 +0000,http://www.wsj.com/articles/seattle-genetics-cancer-drug-trials-on-hold-after-four-patient-deaths-1482846052?mod=yahoo_hs,[$$] Seattle Genetics Cancer-Drug Trials on Hold After Four Patient Deaths
SGEN,SGEN:UW,BBG000BH0SG0,"Why Seattle Genetics, Inc. Got Clobbered Today",2016-12-27 17:51:55 +0000,http://www.fool.com/investing/2016/12/27/why-seattle-genetics-inc-got-clobbered-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Seattle Genetics, Inc. Got Clobbered Today"
SGEN,SGEN:UW,BBG000BH0SG0,FDA places some Seattle Genetics drug trials on hold after 4 deaths,2016-12-27 16:31:34 +0000,http://finance.yahoo.com/news/seattle-genetics-cancer-drug-put-140145014.html,"[Reuters] - Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies. The company's shares fell as much as 15.7 percent to $52.18. Six patients with acute myeloid leukemia (AML), a type of blood cancer, have been identified with liver toxicity and four have died, the company said on Tuesday."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' cancer drug put on clinical hold after 4 deaths,2016-12-27 15:36:03 +0000,http://in.finance.yahoo.com/news/seattle-genetics-cancer-drug-put-153603661.html,Seattle Genetics' cancer drug put on clinical hold after 4 deaths
SGEN,SGEN:UW,BBG000BH0SG0,The powerful bullish signal that could set up 2017 for stock gains,2016-12-27 15:29:22 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=A6BD884E-CB52-11E6-838A-BFE6BAB510E5&siteid=yhoof2,The powerful bullish signal that could set up 2017 for stock gains
SGEN,SGEN:UW,BBG000BH0SG0,"Health Care Sector Update for 12/27/2016: SGEN, IONS, JNJ, PFE, ABT, MRK, AMGN",2016-12-27 15:17:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FONYCDmnwe0/health-care-sector-update-for-12272016-sgen-ions-jnj-pfe-abt-mrk-amgn-cm726382,Top Health care stocks Top Health care stocks JNJ 0 6 JNJ 0 6 PFE 0 5 PFE 0 5 ABT 0 5 ABT 0 5 MRK 0 3 MRK 0 3 AMGN 1 AMGN 1 Health care shares were higher as Tuesday s regular session commencedHealth care shares were higher as Tuesday s regular session commenced In
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Shares Hammered on Clinical Holds,2016-12-27 14:15:52 +0000,http://finance.yahoo.com/news/seattle-genetics-shares-hammered-clinical-141552101.html,Seattle Genetics Shares Hammered on Clinical Holds
SGEN,SGEN:UW,BBG000BH0SG0,"Pre-Market Most Active for Dec 27, 2016 :  SDRL, DNR, CHK, DB, SWN, VALE, CNAT, NVDA, SGEN, MU, SGYP, CLNE",2016-12-27 13:57:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VYtFWxiAHKM/pre-market-most-active-for-dec-27-2016-sdrl-dnr-chk-db-swn-vale-cnat-nvda-sgen-mu-sgyp-clne-cm726156,The NASDAQ 100 Pre Market Indicator is up 6 18 to 4 946 2 The total Pre Market volume is currently 4 074 072 shares traded The following are the most active stocks for the pre market session Seadrill Limited SDRL is 0 17 at 3 56 with 249 520 shares traded SDRL
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics shares halted on news of FDA holds on several early-stage clinical trials,2016-12-27 13:33:03 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CA7D0F3E-BE22-4AF8-900B-7026D7D79460&siteid=yhoof2,Seattle Genetics shares halted on news of FDA holds on several early-stage clinical trials
SGEN,SGEN:UW,BBG000BH0SG0,FDA puts clinical hold on Seattle Genetics' cancer drug after 4 deaths,2016-12-27 13:28:11 +0000,http://finance.yahoo.com/news/fda-puts-clinical-hold-seattle-132437961.html,"[Reuters] - Seattle Genetics Inc said on Tuesday that four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage trials. The drug, vadastuximab talirine, is being tested to treat acute myeloid leukemia, a type of blood cancer. Six patients have been identified with liver toxicity, and four have died, the company said."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A),2016-12-27 13:12:09 +0000,http://www.publicnow.com/view/0992B11C2FB036E98C49840A73C756B5AB334BA3,"[at noodls] - -Enrollment Continues on Phase 3 CASCADE Trial in Acute Myeloid Leukemia and Phase 1/2 Trial in Myelodysplastic Syndrome- BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 27, 2016-- Seattle Genetics, Inc. (Nasdaq:SGEN), ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A),2016-12-27 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-announces-clinical-hold-130000767.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine in acute myeloid leukemia ."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Inc. (SGEN) Is Sinking On News Of FDA Clinical Holds,2016-12-27 09:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L5fBjWIh6l4/seattle-genetics-inc-sgen-is-sinking-on-news-of-fda-clinical-holds-20161227-00199,Seattle Genetics Inc. (SGEN) Is Sinking On News Of FDA Clinical Holds
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Clinical Hold On Vadastuximab Talirine Trials,2016-12-27 08:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M9F1gg2km0g/seattle-genetics-announces-clinical-hold-on-vadastuximab-talirine-trials-20161227-00128,Seattle Genetics Announces Clinical Hold On Vadastuximab Talirine Trials
SGEN,SGEN:UW,BBG000BH0SG0,"ETFs with exposure to Seattle Genetics, Inc. : December 21, 2016",2016-12-21 17:48:54 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-seattle-genetics-inc-december-21-2016/,"ETFs with exposure to Seattle Genetics, Inc. : December 21, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : December 21, 2016",2016-12-21 15:00:21 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-value-analysis-nasdaqsgen-december-21-2016/,"Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : December 21, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,2016-12-20 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-present-j-p-130000861.html,"[Business Wire] - Seattle Genetics, Inc. announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 2:30 p.m."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : December 20, 2016",2016-12-20 12:39:38 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-sgen-us-december-20-2016/,"Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : December 20, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers",2016-12-16 21:41:21 +0000,http://biz.yahoo.com/e/161216/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers"
SGEN,SGEN:UW,BBG000BH0SG0,"Celldex Therapeutics, Inc.'s Biggest Win in 2016",2016-12-11 17:06:01 +0000,http://www.fool.com/investing/2016/12/10/celldex-therapeutics-incs-biggest-win-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Celldex Therapeutics, Inc.'s Biggest Win in 2016"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in Patients with Metastatic Breast Cancer at San Antonio Breast Cancer Symposium,2016-12-10 13:30:00 +0000,http://finance.yahoo.com/news/seattle-genetics-highlights-phase-1-133000787.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer , with particular focus on triple-negative MBC , at the 39th San Antonio Breast Cancer Symposium taking place in San Antonio, Texas, December 6-10, 2016."
SGEN,SGEN:UW,BBG000BH0SG0,Why Seattle Genetics Stock Surged Higher in November,2016-12-09 16:58:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5t3B62UiRMs/why-seattle-genetics-stock-surged-higher-in-november-cm719317,Image source Getty Images What happened According to data from S amp P Global Market Intelligence shares of cancer specialist Seattle Genetics NASDAQ SGEN rose by 16 3 last month presumably as a direct result of Donald Trump s surprise win over Hillary Clinton
SGEN,SGEN:UW,BBG000BH0SG0,Why Seattle Genetics Stock Surged Higher in November,2016-12-09 15:26:06 +0000,http://www.fool.com/investing/2016/12/09/why-seattle-genetics-stock-surged-higher-in-novemb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Seattle Genetics Stock Surged Higher in November
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting,2016-12-06 00:30:00 +0000,http://finance.yahoo.com/news/seattle-genetics-bristol-myers-squibb-003000062.html,"[Business Wire] - Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS in combination with Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting,2016-12-05 18:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-highlights-long-term-180000754.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today highlighted long-term follow-up data evaluating ADCETRIS in T-cell lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting",2016-12-05 15:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-highlights-phase-1-150000871.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today highlighted three oral data presentations on vadastuximab talirine in patients with acute myeloid leukemia at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016."
SGEN,SGEN:UW,BBG000BH0SG0,Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma,2016-12-03 22:00:00 +0000,http://au.finance.yahoo.com/news/takeda-seattle-genetics-report-positive-220000307.html,"[Business Wire] - CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash.--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting,2016-12-03 20:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-presents-phase-1b-200000392.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today highlighted phase 1b data evaluating vadastuximab talirine in combination with the frontline standard of care regimen for induction for younger patients with newly diagnosed acute myeloid leukemia in an oral presentation at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting,2016-12-03 18:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-presents-data-phase-180000349.html,"[Business Wire] - Seattle Genetics, Inc. , a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS combination therapy in frontline diffuse large B-cell lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016."
SGEN,SGEN:UW,BBG000BH0SG0,"ETFs with exposure to Seattle Genetics, Inc. : December 2, 2016",2016-12-02 18:13:02 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-seattle-genetics-inc-december-2-2016/,"ETFs with exposure to Seattle Genetics, Inc. : December 2, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC",2016-12-01 21:52:32 +0000,http://www.investors.com/news/technology/biotechs-aerie-regeneron-tesaro-could-rocket-or-become-ma-fodder/,"Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC"
SGEN,SGEN:UW,BBG000BH0SG0,"Hedge Funds Are Coming Back to Seattle Genetics, Inc. (SGEN)",2016-12-01 19:12:57 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-coming-back-to-seattle-genetics-inc-sgen-493928/,"Hedge Funds Are Coming Back to Seattle Genetics, Inc. (SGEN)"
SGEN,SGEN:UW,BBG000BH0SG0,[$$] Three Biotechs With Bullish Insider Buying,2016-12-01 11:11:00 +0000,http://www.barrons.com/articles/three-biotechs-with-bullish-insider-buying-1480590696?mod=yahoobarrons&ru=yahoo,[$$] Three Biotechs With Bullish Insider Buying
SGEN,SGEN:UW,BBG000BH0SG0,"After Hours Most Active for Nov 30, 2016 :  FDC, INFO, MSFT, BAC, SFUN, BMY, AAPL, SIRI, INTC, NRG, EPD, SGEN",2016-11-30 22:05:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wDDkHgW8sU0/after-hours-most-active-for-nov-30-2016-fdc-info-msft-bac-sfun-bmy-aapl-siri-intc-nrg-epd-sgen-cm716039,The NASDAQ 100 After Hours Indicator is up 1 54 to 4 812 35 The total After hours volume is currently 93 435 420 shares traded The following are the most active stocks for the after hours session First Data Corporation FDC is unchanged at 14 57 with 11 101 653
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting,2016-11-29 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-webcast-investor-analyst-130000036.html,"[Business Wire] - Seattle Genetics, Inc. announced today that the company will webcast an investor and analyst event on Monday, December 5, 2016 during the 58th American Society of Hematology Annual Meeting in San Diego, CA."
SGEN,SGEN:UW,BBG000BH0SG0,Friday's ETF with Unusual Volume: FNY,2016-11-18 18:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/okPLt2Vk-M0/fridays-etf-with-unusual-volume-fny-cm711337,The First Trust Mid Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Friday with over 159 000 shares traded versus three month average volume of about 26 000 Shares of FNY were down about 0 1 on the day Components of that ETF with the highest volume
SGEN,SGEN:UW,BBG000BH0SG0,[$$] Biotech M&A Could Surge Under Trump,2016-11-15 17:16:00 +0000,http://www.barrons.com/articles/biotech-m-a-could-surge-under-trump-1479230159?mod=yahoobarrons&ru=yahoo,[$$] Biotech M&A Could Surge Under Trump
SGEN,SGEN:UW,BBG000BH0SG0,Could Trump 'Make Drug Development Great Again'?,2016-11-14 21:06:56 +0000,http://www.investors.com/news/technology/could-trump-make-drug-development-great-again-biotechs-see-rally/,Could Trump 'Make Drug Development Great Again'?
SGEN,SGEN:UW,BBG000BH0SG0,"Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks",2016-11-14 18:21:11 +0000,http://www.insidermonkey.com/blog/incyte-corporation-incy-seattle-genetics-inc-sgen-two-more-top-healthcare-hedge-fund-loves-these-stocks-485619/,"Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks"
SGEN,SGEN:UW,BBG000BH0SG0,"Massive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife, CBRE, Seattle Genetics and More",2016-11-13 15:15:17 +0000,http://247wallst.com/investing/2016/11/13/massive-carl-icahn-trades-highlights-huge-insider-buying-week-hertz-global-herbalife-cbre-group-seattle-genetics-and-more/,"Massive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife, CBRE, Seattle Genetics and More"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics moves up FDA timeline for cash cow drug Adcetris,2016-11-11 22:24:27 +0000,http://www.bizjournals.com/seattle/news/2016/11/11/seattle-genetics-adcetris-fda-approval-drug-trials.html?ana=yahoo,Seattle Genetics moves up FDA timeline for cash cow drug Adcetris
SGEN,SGEN:UW,BBG000BH0SG0,"Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?",2016-11-10 21:01:53 +0000,http://www.investors.com/news/technology/could-trumps-tax-cut-proposal-republican-congress-spur-biotech-ma/,"Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma,2016-11-10 13:11:06 +0000,http://www.publicnow.com/view/CAF94ABF42B791305DA93811DDC3A273C8B286DD,[at noodls] - -Submission of Supplemental Biologics License Application for ADCETRIS in CD30-Expressing CTCL Planned in First Half of 2017- -Positive Phase 3 ALCANZA Trial Data Evaluating ADCETRIS in CTCL to be Highlighted ...
SGEN,SGEN:UW,BBG000BH0SG0,Why These Biotechs Saw Double-Digit Gains Today,2016-11-09 20:55:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8wMDZU5MkI/why-these-biotechs-saw-double-digit-gains-today-cm706737,Image source Getty Images What happened ImmunoGen NASDAQ IMGN Seattle Genetics NASDAQ SGEN Exelixis NASDAQ EXEL Alnylam Pharmaceuticals NASDAQ ALNY Momenta Pharmaceuticals NASDAQ MNTA and bluebird bio NASDAQ BLUE are all up at
SGEN,SGEN:UW,BBG000BH0SG0,Why These Biotechs Saw Double-Digit Gains Today,2016-11-09 19:25:20 +0000,http://www.fool.com/investing/2016/11/09/why-these-biotechs-saw-double-digit-gains-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why These Biotechs Saw Double-Digit Gains Today
SGEN,SGEN:UW,BBG000BH0SG0,"FXH, WCG, SGEN, UTHR: Large Outflows Detected at ETF",2016-11-08 19:40:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DiyeO0PYCKU/fxh-wcg-sgen-uthr-large-outflows-detected-at-etf-cm705695,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the First Trust Health Care AlphaDEX Fund Symbol FXH where we have detected an approximate 51 0 million dollar outflow that s a 5 2 decrease week over week
SGEN,SGEN:UW,BBG000BH0SG0,Health Care Sector Update for 11/08/2016: SGEN,2016-11-08 15:32:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KiCGgEdMbQM/health-care-sector-update-for-11082016-sgen-cm705517,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 2 PFE 0 2 ABT flatABT flat MRK 0 2 MRK 0 2 AMGN 0 7 AMGN 0 7 Health care shares were mainly higher in pre market trade on Tuesday Health care shares were mainly higher in pre market trade on Tuesday
SGEN,SGEN:UW,BBG000BH0SG0,Analyst Has 4 Biotech Stocks to Buy Now as Risk Has Dropped Dramatically,2016-11-08 14:55:40 +0000,http://247wallst.com/healthcare-business/2016/11/08/analyst-has-4-biotech-stocks-to-buy-now-as-risk-has-dropped-dramatically/,Analyst Has 4 Biotech Stocks to Buy Now as Risk Has Dropped Dramatically
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma,2016-11-08 13:17:11 +0000,http://www.publicnow.com/view/A841F2A2F4D67D14F24C2AA2C788C2BAF051E510,"[at noodls] - http://www.businesswire.com/news/home/20161108005313/en/ Patients in ECHELON-2 were randomized to receive a novel combination regimen consisting of ADCETRIS plus cyclophosphamide (C), doxorubicin (H) and ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics To Present At Credit Suisse Conference; Webcast At 12:00 PM ET,2016-11-08 11:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OM9a8VgbtRM/seattle-genetics-to-present-at-credit-suisse-conference-webcast-at-1200-pm-et-20161108-00811,Seattle Genetics To Present At Credit Suisse Conference; Webcast At 12:00 PM ET
SGEN,SGEN:UW,BBG000BH0SG0,Johnson & Johnson To Present At Credit Suisse Conference; Webcast At 12:00 PM ET,2016-11-08 11:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t7md5ImyAys/johnson--johnson-to-present-at-credit-suisse-conference-webcast-at-1200-pm-et-20161108-00812,Johnson & Johnson To Present At Credit Suisse Conference; Webcast At 12:00 PM ET
SGEN,SGEN:UW,BBG000BH0SG0,"Which Four Biotechs Are Derisked, Buyable Ahead of Election Day?",2016-11-07 21:29:22 +0000,http://www.investors.com/news/technology/which-four-biotechs-are-derisked-buyable-ahead-of-election-day/,"Which Four Biotechs Are Derisked, Buyable Ahead of Election Day?"
SGEN,SGEN:UW,BBG000BH0SG0,"Insiders Buy Herbalife, Sell MasterCard",2016-11-07 10:48:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GJBa3TjnQAc/insiders-buy-herbalife-sell-mastercard-cm704668,The All in One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to duration to October 6 and November 6 and All Insider Sales to 5 According to the
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company’s Expanding Global Leadership in the Development of Innovative Antibody-Drug Conjugates,2016-11-03 20:09:30 +0000,http://www.publicnow.com/view/2CFFCEDFEBEFB0A832846495121D5B21244BA6D0,"[at noodls] - Oral Presentation on Phase 3 ALCANZA Trial in CD30-Expressing Cutaneous T-Cell Lymphoma Breadth of Data on ADCETRIS® (Brentuximab Vedotin), Vadastuximab Talirine (SGN-CD33A) and Other Pipeline Programs ..."
SGEN,SGEN:UW,BBG000BH0SG0,Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting,2016-11-03 16:00:00 +0000,http://au.finance.yahoo.com/news/takeda-present-broad-range-clinical-160000395.html,"[Business Wire] - CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESSWIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 16 company-sponsored abstracts at the 58 th American ..."
SGEN,SGEN:UW,BBG000BH0SG0,4 stocks to watch,2016-11-02 18:37:53 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C2E1D926-A94C-49DC-8129-F84F76F34346&siteid=yhoof2,4 stocks to watch
SGEN,SGEN:UW,BBG000BH0SG0,"ETF’s with exposure to Seattle Genetics, Inc. : November 2, 2016",2016-11-02 18:11:40 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-seattle-genetics-inc-november-2-2016/,"ETF’s with exposure to Seattle Genetics, Inc. : November 2, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,Four Medical And Biotech Stock Charts To Watch,2016-11-02 17:25:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/11/02/four-medical-and-biotech-stock-charts-to-watch/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Four Medical And Biotech Stock Charts To Watch
SGEN,SGEN:UW,BBG000BH0SG0,4 Medical And Biotech Stocks to Watch,2016-11-02 14:48:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_w1gwupOUDI/4-medical-and-biotech-stocks-to-watch-cm702453,"By Harry Boxer   Here are 4 bullish charts in the medical and biotech arena, which is starting to heat up again.  Exelixis, Inc. ( EXEL ), which has been in a declining wedge off its September top, made a new low for the move intraday on Tuesday before snapping back to close up 39 cents, or 3.68%, to 10.98, on 4.6"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 1, 2016",2016-11-01 13:58:37 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-sgen-us-earnings-analysis-q3-2016-by-the-numbers-november-1-2016/,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 1, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : November 1, 2016",2016-11-01 12:15:22 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-sgen-us-november-1-2016/,"Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : November 1, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Credit Suisse 25th Annual Healthcare Conference,2016-11-01 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-present-credit-suisse-120000745.html,"[Business Wire] - Seattle Genetics, Inc. announced today that Clay Siegall, Ph.D., President and Chief Executive Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8, at 10:00 a.m."
SGEN,SGEN:UW,BBG000BH0SG0,"5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on Pipeline",2016-10-31 21:15:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dShEf6dEcCY/5-years-after-adcetris-approval-seattle-genetics-inc-still-focused-on-pipeline-cm701365,Image source Getty Images Seattle Genetics NASDAQ SGEN reported third quarter earnings on Thursday but while the biotech s lead drug has been on the market for half a decade it still remains largely a pipeline story You have to skim down to the fourth subhead of the
SGEN,SGEN:UW,BBG000BH0SG0,"5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on Pipeline",2016-10-31 20:03:12 +0000,http://www.fool.com/investing/2016/10/31/5-years-after-adcetris-approval-seattle-genetics-i.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on Pipeline"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Loss Narrower than Expected in Q3,2016-10-28 19:32:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r2WQSJA7A8E/seattle-genetics-sgen-loss-narrower-than-expected-in-q3-cm700470,Seattle Genetics Inc SGEN reported a loss of 23 cents per share narrower than the Zacks Consensus Estimate of a loss of 29 cents but wider than the year ago loss of 21 cents Revenues came in at 106 3 million up 26 5 year over year primarily on the back of strong sales of
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics (SGEN) Loss Narrower than Expected in Q3,2016-10-28 17:55:05 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-loss-narrower-175505171.html,Seattle Genetics (SGEN) Loss Narrower than Expected in Q3
SGEN,SGEN:UW,BBG000BH0SG0,Edited Transcript of SGEN earnings conference call or presentation 27-Oct-16 8:30pm GMT,2016-10-27 23:15:34 +0000,http://finance.yahoo.com/news/edited-transcript-sgen-earnings-conference-231534506.html,Edited Transcript of SGEN earnings conference call or presentation 27-Oct-16 8:30pm GMT
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today,2016-10-27 20:30:00 +0000,http://biz.yahoo.com/cc/9/153999.html,Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Third Quarter 2016 Financial Results,2016-10-27 20:27:25 +0000,http://www.publicnow.com/view/88E8E471652E84ABCE62C13F63B1D55FC70BADE1,"[at noodls] - -Third Quarter 2016 Revenues Were $106.3 Million, Including Record $70.1 Million in ADCETRIS (Brentuximab Vedotin) U.S. and Canada Net Sales- -Broad Presence at Upcoming American Society of Hematology ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 3Q loss,2016-10-27 20:21:57 +0000,http://sg.finance.yahoo.com/news/seattle-genetics-reports-3q-loss-202157992.html,Seattle Genetics reports 3Q loss
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-10-27 20:14:14 +0000,http://biz.yahoo.com/e/161027/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
SGEN,SGEN:UW,BBG000BH0SG0,Q3 2016 Seattle Genetics Inc Earnings Release - After Market Close,2016-10-27 11:07:04 +0000,http://biz.yahoo.com/research/earncal/20161027.html?t=sgen,Q3 2016 Seattle Genetics Inc Earnings Release - After Market Close
SGEN,SGEN:UW,BBG000BH0SG0,First Week of June 2017 Options Trading For Seattle Genetics (SGEN),2016-10-26 16:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aCi84nu68oY/first-week-of-june-2017-options-trading-for-seattle-genetics-sgen-cm698644,Investors in Seattle Genetics Inc Symbol SGEN saw new options become available this week for the June 2017 expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 233 days until expiration the newly available contracts represent
SGEN,SGEN:UW,BBG000BH0SG0,"Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More",2016-10-26 12:45:12 +0000,http://finance.yahoo.com/news/drug-stock-q3-earnings-roster-124512439.html,"Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016,2016-10-20 12:08:06 +0000,http://www.publicnow.com/view/DF7A55033CC96EF4EBB63DFDBE90ABCD4C67B239,"[at noodls] - -ADCETRIS Data Featured in 21 Presentations Broadly Across HL Disease Settings- -Data from Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for classical HL- BOTHELL, ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Noteworthy ETF Outflows: FXH, SGEN, UTHR, LPNT",2016-10-19 16:48:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/85ZV91YsMKQ/noteworthy-etf-outflows-fxh-sgen-uthr-lpnt-cm695415,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the First Trust Health Care AlphaDEX Fund Symbol FXH where we have detected an approximate 23 6 million dollar outflow that s a 2 2 decrease week over week
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics creates new C-suite role as it seeks profitability,2016-10-17 21:45:11 +0000,http://www.bizjournals.com/seattle/blog/health-care-inc/2016/10/seattle-genetics-vaugn-homes-cto-promotiion.html?ana=yahoo,Seattle Genetics creates new C-suite role as it seeks profitability
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : October 17, 2016",2016-10-17 12:50:42 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-sgen-us-october-17-2016/,"Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : October 17, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics",2016-10-13 15:39:00 +0000,https://www.thestreet.com/story/13852472/1/pardon-me-but-i-have-a-few-things-to-say-seattle-genetics-biomarin-sarepta-tg-therapeutics.html?puc=yahoo&cm_ven=YAHOO,"Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics"
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-10-12 21:17:00 +0000,http://biz.yahoo.com/e/161012/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
SGEN,SGEN:UW,BBG000BH0SG0,SGEN Crosses Above Average Analyst Target,2016-10-11 14:18:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1F9IkzCkpQU/sgen-crosses-above-average-analyst-target-cm691761,In recent trading shares of Seattle Genetics Inc Symbol SGEN have crossed above the average analyst 12 month target price of 57 00 changing hands for 57 25 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress",2016-10-07 13:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-agensys-affiliate-astellas-130000518.html,"[Business Wire] - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin and ASG-15ME at the European Society for Medical Oncology Congress being held October 7-11, 2016 in Copenhagen, Denmark."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial Results on October 27, 2016",2016-10-06 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-host-conference-call-120000312.html,"[Business Wire] - Seattle Genetics, Inc. announced today that it will report its third quarter 2016 financial results on Thursday, October 27 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces Executive Promotions and Leadership Appointment,2016-10-04 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-announces-executive-promotions-120000724.html,"[Business Wire] - Seattle Genetics, Inc. today announced two executive promotions and an executive appointment to the company’s clinical development leadership team."
SGEN,SGEN:UW,BBG000BH0SG0,[$$] Two Cancer Biotechs See Bullish Insider Buying,2016-09-27 10:19:00 +0000,http://www.barrons.com/articles/two-cancer-biotechs-see-bullish-insider-buying-1474971572?mod=yahoobarrons&ru=yahoo,[$$] Two Cancer Biotechs See Bullish Insider Buying
SGEN,SGEN:UW,BBG000BH0SG0,3 Biotechs That Could Be M&A Targets,2016-09-24 17:20:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NmRMs_S2siU/3-biotechs-that-could-be-ma-targets-cm684176,Image source Getty Images After Pfizer Inc agreed to pay 14 times forecast sales for 2016 160 to acquire cancer drugmaking pure play Medivation last month shares in other cancer focused biotech companies shot higher While it doesn t make sense to buy shares in all
SGEN,SGEN:UW,BBG000BH0SG0,3 Biotechs That Could Be M&A Targets,2016-09-24 16:09:27 +0000,http://www.fool.com/investing/2016/09/24/3-biotechs-that-could-be-ma-targets.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs That Could Be M&A Targets
SGEN,SGEN:UW,BBG000BH0SG0,Blue Jay Capital Betting On Big Returns From These Healthcare Stocks,2016-09-22 14:52:13 +0000,http://www.insidermonkey.com/blog/blue-jay-capital-betting-on-big-returns-from-these-healthcare-stocks-475956/,Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia,2016-09-19 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-initiates-phase-1-120000454.html,"[Business Wire] - Seattle Genetics, Inc. today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD123A for patients with relapsed or refractory acute myeloid leukemia ."
SGEN,SGEN:UW,BBG000BH0SG0,"Massive Buffett Trade Again Highlights Insider Buying: Phillips 66, Seattle Genetics, Penske Automotive, Wisdom Tree Investments and More",2016-09-18 14:02:19 +0000,http://247wallst.com/investing/2016/09/18/massive-buffett-trade-again-highlights-insider-buying-phillips-66-seattle-genetics-penske-automotive-wisdom-tree-investments-and-more/,"Massive Buffett Trade Again Highlights Insider Buying: Phillips 66, Seattle Genetics, Penske Automotive, Wisdom Tree Investments and More"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake,2016-09-16 12:05:56 +0000,http://www.insidermonkey.com/blog/seattle-genetics-inc-sgen-baker-bros-advisors-raises-stake-474949/,Seattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake
SGEN,SGEN:UW,BBG000BH0SG0,Aerie Pharmaceuticals Skyrockets On Eye Drug News,2016-09-15 20:42:19 +0000,http://www.investors.com/news/technology/aerie-pharmaceuticals-skyrockets-on-eye-drug-news/,Aerie Pharmaceuticals Skyrockets On Eye Drug News
SGEN,SGEN:UW,BBG000BH0SG0,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar",2016-09-14 20:27:26 +0000,http://www.investors.com/research/ibd-industry-themes/bevy-of-biotech-stocks-healthy-sarepta-bluebird-exelixis-soar/,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar"
SGEN,SGEN:UW,BBG000BH0SG0,"Watch Oracle, Casinos, Biotechs For Thursday's Investing Action Plan",2016-09-14 20:22:14 +0000,http://www.investors.com/research/investing-action-plan/watch-oracle-casinos-biotechs-for-thurdays-investing-action-plan/,"Watch Oracle, Casinos, Biotechs For Thursday's Investing Action Plan"
SGEN,SGEN:UW,BBG000BH0SG0,5 Stocks Insiders Love Right Now,2016-09-14 17:36:00 +0000,https://www.thestreet.com/story/13729124/1/5-stocks-insiders-love-right-now.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Insiders Love Right Now
SGEN,SGEN:UW,BBG000BH0SG0,Major Averages Close Mixed Following Recent Volatility - U.S. Commentary,2016-09-14 16:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_duuIn8OZLg/major-averages-close-mixed-following-recent-volatility--us-commentary-20160914-00994,Major Averages Close Mixed Following Recent Volatility - U.S. Commentary
SGEN,SGEN:UW,BBG000BH0SG0,Major Averages Close Mixed Following Recent Volatility - U.S. Commentary,2016-09-14 16:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_fCWxaxgMuk/major-averages-close-mixed-following-recent-volatility--us-commentary-20160914-00995,Major Averages Close Mixed Following Recent Volatility - U.S. Commentary
SGEN,SGEN:UW,BBG000BH0SG0,These 5 NASDAQ Stocks Just Hit Their 52-Week Highs,2016-09-14 14:49:14 +0000,http://www.insidermonkey.com/blog/these-5-nasdaq-stocks-just-hit-their-52-week-highs-474492/,These 5 NASDAQ Stocks Just Hit Their 52-Week Highs
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics To Participate In Morgan Stanley Global Conference At 9:10 AM,2016-09-13 08:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cbiuTZRkjrw/seattle-genetics-to-participate-in-morgan-stanley-global-conference-at-910-am-20160913-00433,Seattle Genetics To Participate In Morgan Stanley Global Conference At 9:10 AM
SGEN,SGEN:UW,BBG000BH0SG0,"15,000 shares bought by Seattle Genetics Director",2016-09-09 16:31:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hHjVn9hog_s/15000-shares-bought-by-seattle-genetics-director-cm677012,Felix Baker 160 Director at Seattle Genetics SGEN bought 414 016 shares of the company s common stock on September 8 The shares were purchased at 48 43 for a total of 160 20 050 794 88 160 160 160 InvestorsKeyhole Trade Alert IK gt The technicals for SGEN 50 60
SGEN,SGEN:UW,BBG000BH0SG0,Agios Stock Soars As Partner Celgene Preps Drug Filing,2016-09-07 20:40:24 +0000,http://www.investors.com/news/technology/agios-stock-soars-as-partner-celgene-preps-drug-filing/,Agios Stock Soars As Partner Celgene Preps Drug Filing
SGEN,SGEN:UW,BBG000BH0SG0,"Wednesday's ETF Movers: FBT, GDXJ",2016-09-07 17:17:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-TI24VDrbk/wednesdays-etf-movers-fbt-gdxj-cm675697,In trading on Wednesday the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs up about 1 4 on the day Components of that ETF showing particular strength include shares of Agios Pharmaceuticals up about 24 4 and shares of Seattle Genetics up about 4 8 on the
SGEN,SGEN:UW,BBG000BH0SG0,"ETF’s with exposure to Seattle Genetics, Inc. : September 7, 2016",2016-09-07 15:08:09 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-seattle-genetics-inc-september-7-2016/,"ETF’s with exposure to Seattle Genetics, Inc. : September 7, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference,2016-09-06 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-present-morgan-stanley-120000053.html,"[Business Wire] - Seattle Genetics, Inc. announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. Eastern Time."
SGEN,SGEN:UW,BBG000BH0SG0,"[$$] Seattle Genetics Stock Surges, Execs Sell",2016-08-26 14:46:00 +0000,http://www.barrons.com/articles/seattle-genetics-stock-surges-execs-sell-1472222607?mod=yahoobarrons&ru=yahoo,"[$$] Seattle Genetics Stock Surges, Execs Sell"
SGEN,SGEN:UW,BBG000BH0SG0,We Did The Math BBH Can Go To $136,2016-08-26 12:46:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jGoHDMYlrn4/we-did-the-math-bbh-can-go-to-136-cm670448,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
SGEN,SGEN:UW,BBG000BH0SG0,"ETF’s with exposure to Seattle Genetics, Inc. : August 25, 2016",2016-08-25 14:29:26 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-seattle-genetics-inc-august-25-2016/,"ETF’s with exposure to Seattle Genetics, Inc. : August 25, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss",2016-08-23 13:44:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/23/4-biotech-buyout-targets-for-gilead-sanofi-after-medivation-miss/?mod=yahoobarrons&ru=yahoo,"4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss"
SGEN,SGEN:UW,BBG000BH0SG0,"ImmunoGen, Inc. Gets the FDA Green Light (for Its Trial Design)",2016-08-09 21:56:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PVabKjzQpTw/immunogen-inc-gets-the-fda-green-light-for-its-trial-design-cm662881,"Image source  Getty Images.  ImmunoGen (NASDAQ  IMGN) reported earnings for its fourth fiscal quarter. Now that the company sold its rights to royalty on Roche's Kadcyla, ImmunoGen is like any other development"
SGEN,SGEN:UW,BBG000BH0SG0,"ETF’s with exposure to Seattle Genetics, Inc. : August 9, 2016",2016-08-09 18:07:37 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-seattle-genetics-inc-august-9-2016/,"ETF’s with exposure to Seattle Genetics, Inc. : August 9, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 15:53:10 +0000,http://www.capitalcube.com/blog/index.php/seattle-genetics-inc-sgen-us-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
SGEN,SGEN:UW,BBG000BH0SG0,"DVAX To Face FDA Panel, BMY's Opdivo Disappoints, MRK Scores Big With FDA Nod",2016-08-07 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gyDgXustNhc/dvax-to-face-fda-panel-bmys-opdivo-disappoints-mrk-scores-big-with-fda-nod-20160807-00048,"DVAX To Face FDA Panel, BMY's Opdivo Disappoints, MRK Scores Big With FDA Nod"
SGEN,SGEN:UW,BBG000BH0SG0,Bloomberg TVs' Doolittle Breaks Down Nasdaq Biotech Movers,2016-08-01 14:33:00 +0000,https://www.thestreet.com/story/13659405/1/bloomberg-tvs-doolittle-breaks-down-nasdaq-biotech-movers.html?puc=yahoo&cm_ven=YAHOO,Bloomberg TVs' Doolittle Breaks Down Nasdaq Biotech Movers
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-08-01 11:10:22 +0000,http://biz.yahoo.com/e/160801/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
SGEN,SGEN:UW,BBG000BH0SG0,Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma,2016-08-01 11:01:04 +0000,http://www.publicnow.com/view/920610706A3463DEF8ED1B3E7A85A8578D2E168B,"[at noodls] - -Randomized Phase 3 Clinical Trial with ADCETRIS Met Primary Endpoint, Demonstrating Highly Statistically Significant Improvement in Rate of Objective Response Lasting at Least Four Months- BOTHELL, Wash., ..."
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics, Inc. Making the Most of It (and Then Some)",2016-07-29 23:25:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-G8YNuqvUgY/seattle-genetics-inc-making-the-most-of-it-and-then-some-cm657614,"Image source  Getty Images.  Seattle Genetics (NASDAQ  SGEN) might only have one drug on the market for now, but it's making the most of it, with sales continuing to grow, and the"
SGEN,SGEN:UW,BBG000BH0SG0,"Delving Into Seattle Genetics, Inc. (SGEN)’s Upcoming Readout",2016-07-28 15:35:55 +0000,http://www.insidermonkey.com/blog/delving-into-seattle-genetics-inc-sgens-upcoming-readout-466861/,"Delving Into Seattle Genetics, Inc. (SGEN)’s Upcoming Readout"
SGEN,SGEN:UW,BBG000BH0SG0,"Wednesday's ETF Movers: XBI, FXN",2016-07-27 19:22:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mBCG0UGnHCI/wednesdays-etf-movers-xbi-fxn-cm655881,"In trading on Wednesday, the SPDR S&P Biotech ETF ( XBI ) is outperforming other ETFs, up about 1.7% on the day. Components of that ETF showing particular strength include shares of Amicus Therapeutics ( FOLD ), up about"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2,2016-07-27 14:28:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p8ZeRmYrsCc/seattle-genetics-sgen-loss-narrower-than-expected-in-q2-cm655652,"Seattle Genetics, Inc.SGEN reported a loss of 23 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 38 cents. Revenues came in at $95.4 million, up"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2,2016-07-27 13:06:01 +0000,http://finance.yahoo.com/news/seattle-genetics-sgen-loss-narrower-130601927.html,Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2
SGEN,SGEN:UW,BBG000BH0SG0,Edited Transcript of SGEN earnings conference call or presentation 26-Jul-16 8:30pm GMT,2016-07-27 05:37:36 +0000,http://finance.yahoo.com/news/edited-transcript-sgen-earnings-conference-053736294.html,Edited Transcript of SGEN earnings conference call or presentation 26-Jul-16 8:30pm GMT
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 2Q loss,2016-07-26 20:53:41 +0000,http://sg.finance.yahoo.com/news/seattle-genetics-reports-2q-loss-205341001.html,Seattle Genetics reports 2Q loss
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-07-26 20:22:21 +0000,http://biz.yahoo.com/e/160726/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Second Quarter 2016 Financial Results,2016-07-26 20:02:00 +0000,http://finance.yahoo.com/news/seattle-genetics-reports-second-quarter-200200779.html,"[Business Wire] - Seattle Genetics, Inc. today reported financial results for the second quarter ended June 30, 2016. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, vadastuximab talirine activities and progress with its pipeline of antibody-drug conjugates and other proprietary programs."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Q2 16 Earnings Conference Call At 4:30 PM ET,2016-07-26 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WO74dnpxXWk/seattle-genetics-q2-16-earnings-conference-call-at-430-pm-et-20160726-01060,Seattle Genetics Q2 16 Earnings Conference Call At 4:30 PM ET
SGEN,SGEN:UW,BBG000BH0SG0,Q2 2016 Seattle Genetics Inc Earnings Release - After Market Close,2016-07-26 11:07:04 +0000,http://biz.yahoo.com/research/earncal/20160726.html?t=sgen,Q2 2016 Seattle Genetics Inc Earnings Release - After Market Close
SGEN,SGEN:UW,BBG000BH0SG0,What's in Store for these 5 Drug Stocks in Q2 Earnings?,2016-07-25 13:10:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QoEBIG2Jy2E/whats-in-store-for-these-5-drug-stocks-in-q2-earnings-cm653960,"Q2 earnings season is picking up pace with 1,000 companies including 189 S&P 500 members scheduled to report this week. So far, about 126 S&P 500 members have reported results accounting for 32.7% of the index's total market capitalization."
SGEN,SGEN:UW,BBG000BH0SG0,What's in Store for these 5 Drug Stocks in Q2 Earnings?,2016-07-25 12:24:12 +0000,http://finance.yahoo.com/news/whats-store-5-drug-stocks-122412110.html,What's in Store for these 5 Drug Stocks in Q2 Earnings?
SGEN,SGEN:UW,BBG000BH0SG0,3 Stocks We're Buying Again,2016-07-21 14:14:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pldkZsiRi8g/3-stocks-were-buying-again-cm652488,Image source  Getty Images.  Searching for your next investment can be difficult. Too often investors venture into industries or companies they are less familiar with when the best investment they can make is
SGEN,SGEN:UW,BBG000BH0SG0,3 Stocks We're Buying Again,2016-07-21 12:06:00 +0000,http://www.fool.com/investing/2016/07/21/3-stocks-were-buying-again.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks We're Buying Again
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood,2016-07-18 14:00:00 +0000,http://au.finance.yahoo.com/news/seattle-genetics-takeda-announce-publication-140000670.html,"[Business Wire] - BOTHELL, Wash., CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESSWIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS ..."
SGEN,SGEN:UW,BBG000BH0SG0,3 Primary Ways Researchers Are Combatting Cancer,2016-07-16 17:12:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5kjgveQ70qk/3-primary-ways-researchers-are-combatting-cancer-cm650196,"Image source  Getty Images.  Among the countless ailments a person can be diagnosed with, cancer is arguably the scariest. Worse yet, the odds of developing cancer are probably higher than many realize. Data from"
SGEN,SGEN:UW,BBG000BH0SG0,3 Primary Ways Researchers Are Combatting Cancer,2016-07-16 15:41:00 +0000,http://www.fool.com/investing/2016/07/16/3-primary-ways-researchers-are-combatting-cancer.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Primary Ways Researchers Are Combatting Cancer
SGEN,SGEN:UW,BBG000BH0SG0,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers",2016-07-15 20:41:15 +0000,http://biz.yahoo.com/e/160715/sgen8-k.html,"SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers"
SGEN,SGEN:UW,BBG000BH0SG0,"5 Things Celldex Therapeutics, Inc. Wants You to Know",2016-07-13 22:49:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4IcN3FNUHck/5-things-celldex-therapeutics-inc-wants-you-to-know-cm648909,"Image source  Getty Images.  Clinical stage biotech Celldex Therapeutics (NASDAQ  CLDX) is down about 70% year to date, after its first candidate to reach late stage development failed in March. However, the"
SGEN,SGEN:UW,BBG000BH0SG0,"Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial Results on July 26, 2016",2016-07-13 12:00:00 +0000,http://finance.yahoo.com/news/seattle-genetics-host-conference-call-120000231.html,"[Business Wire] - Seattle Genetics, Inc. announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update."
SGEN,SGEN:UW,BBG000BH0SG0,AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.,2016-07-12 16:54:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LKRz3X4c9GM/abbvies-abt-414-gets-rare-pediatric-disease-status-in-us-cm648067,"AbbVie Inc.ABBV announced that its oncology candidate, ABT 414, has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with epidermal growth factor receptor (EGFR) amplified diffuse intrinsic pontine glioma (DIPG) highly aggressive"
SGEN,SGEN:UW,BBG000BH0SG0,"Nanobiotix Takes A Big Step, VRTX Broadens Pipeline, PFE Aims High With Javelin",2016-07-08 09:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2LJ0BZgHc-8/nanobiotix-takes-a-big-step-vrtx-broadens-pipeline-pfe-aims-high-with-javelin-20160708-00339,"Nanobiotix Takes A Big Step, VRTX Broadens Pipeline, PFE Aims High With Javelin"
SGEN,SGEN:UW,BBG000BH0SG0,"Nanobiotix Takes A Big Step, VRTX Broadens Pipeline, PFE Aims High With Javelin",2016-07-08 09:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wkyoFYzb1tE/nanobiotix-takes-a-big-step-vrtx-broadens-pipeline-pfe-aims-high-with-javelin-20160708-00340,"Nanobiotix Takes A Big Step, VRTX Broadens Pipeline, PFE Aims High With Javelin"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics/Takeda Adectris' Label Expanded in the EU,2016-07-08 00:37:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IKCVEkaIZ3g/seattle-geneticstakeda-adectris-label-expanded-in-the-eu-cm646131,"Seattle Genetics, Inc.SGEN announced that its partner Takeda Pharmaceutical Company Limited TKPYY has received marketing authorization for the label expansion of its lymphoma drug, Adcetris. The European Commission (EC) has approved the drug for a third indication for the"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics/Takeda Adectris' Label Expanded in the EU,2016-07-07 22:21:10 +0000,http://finance.yahoo.com/news/seattle-genetics-takeda-adectris-label-222110732.html,Seattle Genetics/Takeda Adectris' Label Expanded in the EU
SGEN,SGEN:UW,BBG000BH0SG0,Bargain Buys: These 3 Biopharma Stocks Are All Down Big in 2016,2016-06-30 21:48:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/578iD0l4NVs/bargain-buys-these-3-biopharma-stocks-are-all-down-big-in-2016-cm643487,"Image source  Getty Images.  The U.S. presidential election and the Brexit vote have combined to wreck havoc on biopharma stocks this year. On the bright side, these headwinds appear to have created some"
SGEN,SGEN:UW,BBG000BH0SG0,Stocks Give Back Ground But Remain Positive - U.S. Commentary,2016-06-22 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QIvySGCBte4/stocks-give-back-ground-but-remain-positive--us-commentary-20160622-00606,Stocks Give Back Ground But Remain Positive - U.S. Commentary
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Has Been Heating Up: Time to Buy?,2016-06-11 00:13:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/71EB0_fr0Dg/seattle-genetics-has-been-heating-up-time-to-buy-cm634085,"Image Source  Getty Images.  What Seattle Genetics '(NASDAQ  SGEN) stock rose by more than 11% last month, according to data from S&P Global Market Intelligence . Seattle's stock forged higher despite a"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting,2016-06-06 12:00:00 +0000,http://au.finance.yahoo.com/news/seattle-genetics-astellas-present-asg-120000812.html,"[Business Wire] - CHICAGO & TOKYO--(BUSINESSWIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American ..."
SGEN,SGEN:UW,BBG000BH0SG0,Stocks Close Mostly Higher After Staging Another Recovery - U.S. Commentary,2016-06-02 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WN0SslK1P7E/stocks-close-mostly-higher-after-staging-another-recovery--us-commentary-20160602-01093,Stocks Close Mostly Higher After Staging Another Recovery - U.S. Commentary
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug,2016-05-26 22:04:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JCZkuCIGC3U/seattle-genetics-starts-trial-on-acute-myeloid-leukemia-drug-cm627207,"Seattle Genetics, Inc . SGEN announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN CD33A). The randomized, double blind, placebo controlled trial will evaluate if vadastuximab talirine, in combination with Vidaza or Dacogen, can"
SGEN,SGEN:UW,BBG000BH0SG0,"No Pain, Only Gain For INNL, FDA Panel Backs SNY, Wait Continues For SRPT",2016-05-25 23:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DNmIUDzwdF0/no-pain-only-gain-for-innl-fda-panel-backs-sny-wait-continues-for-srpt-20160525-01241,"No Pain, Only Gain For INNL, FDA Panel Backs SNY, Wait Continues For SRPT"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics To Present At UBS Healthcare Conference; Webcast At 10:30 AM ET,2016-05-24 09:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ivYhzNKZlqw/seattle-genetics-to-present-at-ubs-healthcare-conference-webcast-at-1030-am-et-20160524-00605,Seattle Genetics To Present At UBS Healthcare Conference; Webcast At 10:30 AM ET
SGEN,SGEN:UW,BBG000BH0SG0,July 15th Options Now Available For Seattle Genetics (SGEN),2016-05-23 15:52:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lmx0w_uVgdU/july-15th-options-now-available-for-seattle-genetics-sgen-cm624975,"Investors in Seattle Genetics Inc (Symbol SGEN) saw new options begin trading today, for the July 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the SGEN options chain for the new July"
SGEN,SGEN:UW,BBG000BH0SG0,3 Cancer-Fighting Stocks Making Waves in the Markets,2016-05-23 10:52:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_EyRC9sHqxQ/3-cancer-fighting-stocks-making-waves-in-the-markets-cm624410,"The statistics of the effects of cancer in the U.S. are sobering. By the end of this year, there will be nearly 1.7 million new cancer cases , according to"
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 1Q loss,2016-04-28 21:59:49 +0000,http://sg.finance.yahoo.com/news/seattle-genetics-reports-1q-loss-215949340.html,Seattle Genetics reports 1Q loss
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 4Q loss,2016-02-09 22:11:38 +0000,http://sg.finance.yahoo.com/news/seattle-genetics-reports-4q-loss-221138775.html,Seattle Genetics reports 4Q loss
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,2016-01-05 13:29:18 +0000,http://www.noodls.com/view/ED8ECF4F451B9D3C463FB985E84B07A3A271AAF4,"[at noodls] - --(BUSINESS WIRE)--Jan. 5, 2016-- (NASDAQ:SGEN) announced today that , Ph.D., President and Chief Executive Officer, will present at the 34th Annual on at . Both the presentation and question and answer ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma,2015-12-23 13:27:10 +0000,http://www.noodls.com/view/E6EB0198BDAB2A1C7488BAB11AD1355BC0786716,"[at noodls] - Seattle Genetics, Inc. (Nasdaq: SGEN) and Bristol-Myers Squibb (NYSE:BMY) today announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Presents Phase 1 Data from Novel Antibody-Drug Conjugate SGN-LIV1A at San Antonio Breast Cancer Symposium,2015-12-10 13:17:20 +0000,http://www.noodls.com/view/AA7201336559205425A36F8B41C1D505CAFBEB0A,[at noodls] - First Clinical Data Presentation of SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with Triple Negative Metastatic Breast Cancer SAN ANTONIO--(BUSINESS WIRE)--Dec. ...
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015,2015-12-07 22:03:31 +0000,http://www.noodls.com/view/1790DDB029D037FDA6A54C6C05D23EE6DDD4B1FA,[at noodls] - -Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete ...
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015,2015-12-07 16:03:46 +0000,http://www.noodls.com/view/CD4C562AD6772296CCD1E7AB7E205F9091E898F8,[at noodls] - -Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy- -Data From Multiple Presentations Support Goal to Establish ...
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015,2015-12-06 12:39:06 +0000,http://www.noodls.com/view/B5DB2B016FAAD4227CC7319BF75A052FA2AA0142,[at noodls] - -Updated Data from Phase 1 Clinical Trials Support Further Clinical Evaluation of SGN-CD19A in Randomized Phase 2 Trials: Testing Novel Regimens for Frontline and Relapsed DLBCL- -First Preclinical Data ...
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Oppenheimer Healthcare Conference,2015-12-02 13:07:21 +0000,http://www.noodls.com/view/3041450C1D1EC55B6CF1FB6651FAA0CAED6D8FB9,"[at noodls] - BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 2, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 26th Annual Oppenheimer Healthcare Conference onWednesday, December ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting,2015-12-01 13:23:22 +0000,http://www.noodls.com/view/A70F26096042A98BBB447D0009F3347391A5A194,"[at noodls] - BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 1, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 7, 2015 during the 57th ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia,2015-11-23 13:15:36 +0000,http://www.noodls.com/view/B3FD3E28607A0BA1C07CEDE5ABA4519C3908EAE3,"[at noodls] - -Trial Based on Anti-Leukemic Activity Observed in Ongoing Phase 1 Clinical Trials Evaluating SGN-CD33A in AML- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 23, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs,2015-11-05 21:32:22 +0000,http://www.noodls.com/view/83C53A8601B60EB12C92A427AEF28ED3E1BAD935,"[at noodls] - -ADCETRIS Data Featured in 17 Presentations, Including Eight Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Expressing Malignancies- -Clinical Data for SGN-CD33A ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics reports 3Q loss,2015-10-29 21:13:49 +0000,http://sg.finance.yahoo.com/news/seattle-genetics-reports-3q-loss-211349781.html,Seattle Genetics reports 3Q loss
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Reports Third Quarter 2015 Financial Results,2015-10-29 20:28:18 +0000,http://www.noodls.com/view/D85D3A6E1417E86C20B0EBE79D634A97CC5290EF,"[at noodls] - -Total Third Quarter 2015 Revenues of $84.1 Million, Including Record $59.1 Million in ADCETRIS ® (Brentuximab Vedotin) U.S. and Canada Net Sales- -ADCETRIS 2015 U.S. and Canada Net Sales Guidance Increased ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL),2015-10-29 12:18:13 +0000,http://www.noodls.com/view/D180A81F189B987F0B73557C52037AD86FB83E3B,"[at noodls] - -Trial Based on Data From Phase 1 Trial in B-cell Non-Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 29, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced the initiation of a randomized ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics to Present at Credit Suisse Healthcare Conference,2015-10-28 12:17:04 +0000,http://www.noodls.com/view/4721CD28A20DDCF7343EA1B9E83253A55F2EC9BD,"[at noodls] - BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 28, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, President and Chief Executive Officer, will present at the Credit Suisse Healthcare ..."
SGEN,SGEN:UW,BBG000BH0SG0,Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL),2015-10-27 12:15:15 +0000,http://www.noodls.com/view/16F40C040025B31C8312F6B6A1C00B1AAAB93F97,"[at noodls] - -ECHELON-1 Data Anticipated in 2017 to 2018 Timeframe- BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 27, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical CompanyLimited ..."
